CHILDREN'S ONCOLOGY GROUP

The world's childhood cancer experts

Group Chair
Peter C. Adamson, M.D.
adamson@email.chop.edu

Group Vice Chair
Susan Blaney, M.D.
smblaney@txch.org

Chief Operating Officer
Elizabeth O'Connor, M.P.H.
econnor@childrensoncology group.org

Executive Director of Administration
Kristin Coffan
coffank@email.chop.edu

Group Statistician
Todd Alonzo, Ph.D.
talonzo@childrensoncology group.org

Group Chair's Office
The Children's Hospital of Philadelphia
3501 Civic Center Blvd
CTRB 10060
Philadelphia, PA 19104

P 215 590 6359
F 215 590 7544

Group Operations Center
222 E. Huntington Drive
Suite 100
Monrovia, CA 91016

P 626 447 0064
F 626 445 4334

Statistics & Data Center Headquarters
222 E. Huntington Drive
Suite 100
Monrovia, CA 91016

P 626 447 0064
F 626 445 4334

Gainesville Office
6011 NW 1st Place
Gainesville, FL 32607

P 352 273 0556
F 352 392 8162

A National Cancer Institute-supported member group of the National Clinical Trials Network

September 6, 2016

Martha Kruhm, MS, RAC
Head, Protocol and Information Office
Operations and Informatics Branch
Cancer Therapy Evaluation Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
Executive Plaza North Room 730
Bethesda, MD 20892

Dear Ms. Kruhm,

The Study Committee for **AOST1521**, *A Phase 2 Study of GPNMB-targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; IND# 128248, NSC# 763737), in Recurrent or Refractory Osteosarcoma,* has provided Amendment #1 for CTEP review.

This amendment is being submitted in response to Request for Rapid Response (RRA) from Dr. Jeff Moscow (Jeffery.moscow@nih.gov). Revisions to the protocol are detailed in the pages below.

The AOST1521 study committee looks forward to approval of this amendment. Please contact me with any questions or concerns.

Sincerely,

Meg Stahlman, Protocol Coordinator (for)
Lisa Kopp, DO, AOST1521 Study Chair
Peter Adamson, MD, Children's Oncology Group Chair

SUMMARY OF CHANGES: PROTOCOL DOCUMENT

In accordance with the above discussion, the following specific revisions have been made to the protocol. Additions are in **boldfaced** font and deletions in ~~strikethrough~~ font.

#	Section	Page(s)	Change
1.	Title Page	1	Version date updated and Amendment number updated. .
2.	6.1		Drug monograph revised to use CDX-011 in the title to match the new CAEPR. The date has been updated. Insertion of revised CAEPR (Version 2.1, August 3, 2016) which includes an added new risk: • [redacted]

SUMMARY OF CHANGES: CONSENT DOCUMENT

In accordance with the above discussion, the following specific revisions have been made to the protocol. Additions are in **boldfaced** font and deletions in ~~strikethrough~~ font.

#	Section	Page(s)	Change
1.	Throughout	1	Version date updated. .
2.	Risks of Study	6	Added New Risks: • **Rare: Blood clot which may cause swelling, pain, shortness of breath;** • **Rare: Swelling and redness at the site of the medication injection**

Activated: 02/16/16
Closed:
Version Date: 09/06/16
Amendment: #1

CHILDREN'S ONCOLOGY GROUP

AOST1521

A Phase 2 Study of GPNMB-targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; IND# 128248, NSC# 763737), in Recurrent or Refractory Osteosarcoma

An Intergroup NCTN Phase 2 Study

NCI Supplied Agent: CDX-011 (IND# 128248, NSC# 763737)

IND Sponsor for CDX-011: DCTD, NCI

STUDY CHAIR

Lisa M. Kopp, DO
The University of Arizona Medical Center
1501 North Campbell Avenue, Room 534
Tucson, AZ 85724
Phone: (520) 626-2021
E-mail: lkopp@peds.arizona.edu

Participating Organizations

COG / Children's Oncology Group

ALLIANCE / Alliance for Clinical Trials in Oncology

ECOG-ACRIN / ECOG-ACRIN Cancer Research Group

NRG / NRG Oncology

SWOG / SWOG

CONTACT INFORMATION		
To submit site registration documents:	**For patient enrollments:**	**Submit study data**
CTSU Regulatory Office 1818 Market Street, Suite 1100 Philadelphia, PA 19103 Phone – 1-866-651-CTSU Fax – 215-569-0206 Email: CTSURegulatory@ctsu.coccg.org (for submitting regulatory documents only)	Please refer to the patient enrollment section of the protocol for instructions on using the Oncology Patient Enrollment Network (OPEN) which can be accessed at https://www.ctsu.org/OPEN_SYSTEM/ or https://OPEN.ctsu.org. Contact the CTSU Help Desk with any OPEN-related questions at ctsucontact@westat.com.	Data collection for this study will be done exclusively through Medidata Rave. Please see the Data Submission Schedule in the CRF packet for further instructions.
The most current version of the **study protocol and all supporting documents** must be downloaded from the protocol-specific Web page of the CTSU Member Web site located at https://www.ctsu.org. Access to the CTSU members' website is managed through the Cancer Therapy and Evaluation Program - Identity and Access Management (CTEP-IAM) registration system and requires user log on with CTEP-IAM username and password. Permission to view and download this protocol and its supporting documents is restricted and is based on person and site roster assignment housed in the CTSU RSS.		
For clinical questions (i.e. patient eligibility or treatment-related) contact the Study PI of the Lead Protocol Organization.		
For non-clinical questions (i.e. unrelated to patient eligibility, treatment, or clinical data submission) contact the CTSU Help Desk by phone or e-mail: CTSU General Information Line – 1-888-823-5923, or ctsucontact@westat.com. All calls and correspondence will be triaged to the appropriate CTSU representative.		
The CTSU Website is located at https://www.ctsu.org.		

TABLE OF CONTENTS

STUDY COMMITTEE

STUDY CHAIR
Lisa M. Kopp, DO
Hematology/Oncology
The University of Arizona Medical Center
1501N. Campbell Ave., Room 534
Tucson, AZ 85724
Phone: (520) 626-2021
Email: lkopp@peds.arizona.edu

STUDY VICE CO-CHAIR
Katherine Janeway, MD
Hematology/Oncology
Dana Farber Cancer Institute
450 Brookline Ave Street, Dana 3
Boston, MA 02215
Phone: (617) 632-4994
Fax: (617) 632-5710
E-mail: katherine_janeway@dfci.harvard.edu

STUDY VICE CO-CHAIR
Suman Malempati, MD
Hematology/Oncology
Oregon Health and Science University
3181 SW Sam Jackson Park Road
Portland, OR 97239
Phone: (503) 494-1543
Fax: (503) 494-0714
E-mail: malempat@ohsu.edu

STUDY STATISTICIAN
Mark Krailo, PhD
Biostatistics
Children's Oncology Group
222 E. Huntington Dr., Suite 100
Monrovia, CA. 91016
Phone: (626) 241-1529
Fax: (626) 445-4334
E-mail: mkrailo@childrensoncologygroup.org

STUDY COMMITTEE MEMBERS
Richard G. Gorlick, MD
Hematology/Oncology
Montefiore Medical Center – Moses Campus
Section of Pediatric Hematology/Oncology
3415 Bainbridge Ave, Rosenthal 3rd floor
Bronx, NY. 10467
Phone: (718) 741-2342
Fax: (718) 920-6506
E-mail: rgorlick@montefiore.org

STUDY COMMITTEE MEMBERS
Brenda J. Weigel, MD
Hematology/Oncology
University of Minnesota/Masonic Cancer Center
420 Delaware Street, SE, MMC 366
Minneapolis, MN 55455
Phone: (612) 626-5501
Fax: (612) 624-3913
Email: weig007@umn.edu

Lisa A. Teot, MD
Pathology
Dana-Farber Cancer Institute
300 Longwood Avenue Bader 110
Boston, MA 02115
Phone: (857) 218-4962
Fax: (617) 730-0207
Email: lisa.teot@childrens.harvard.edu

Justin Cates, MD PhD
Pathology
Vanderbilt University/Ingram Cancer Center
1161 21st Avenue South, MCN C-3322
Nashville, TN 37232
Phone: (615) 936-6694
Fax: (615) 322-0511
E-mail: justin.m.cates@vanderbilt.edu

Amy R. Newman, RN
Nursing
Midwest Children's Cancer Center
9000 W. Wisconsin Ave.
Milwaukee, WI 53201
Phone: (414) 266-6931
Fax: (414) 266-3058
E-mail: anewman@chw.org

Victor M. Villalobos, MD, PhD
University of Colorado Denver
1665 Aurora Ct., ACP Rm. 5329 MS F704
Aurora, CO 80045
Phone: (720) 848-0467
Fax: (720) 848-1413
Email: victor.m.villalobos@ucdenver.edu

STUDY COMMITTEE MEMBERS
Joel M. Reid, PhD
Mayo Clinic
200 First Street SW, 19-365 Gonda Building
Rochester, MN 55905
Phone: (507) 284-0822
Fax: (507) 284-3906
E-mail: reid.joel@mayo.edu

Robert Lor Randall, MD FACS
Surgery
Primary Children's Hospital
200 Circle of Hope Drive, Room 4262
Salt Lake City, UT 84112
Phone: (801) 585-0300
Fax: (801) 585-7084
Email: r.lor.randall@hci.utah.edu

Grace Lin, PharmD
Pharmacy
Lucile Packard Children's Hospital Stanford University
725 Welch Road
Palo Alto, CA 94304
Phone: (650) 497-8776
Email: glin@lpch.org

Alisa Eicher, BS CCRP
Clinical Research Associate
Oregon Health and Science University
3181 SW Sam Jackson Park Rd.
Portland, OR 97239-3098
Phone: (503) 418-5336
Fax: (503)418-5337
Email: eichera@ohsu.edu

RESEARCH COORDINATOR
Justin Davis
Children's Oncology Group
Statistics & Data Center
222 E. Huntington Drive, Suite 100
Monrovia, CA 91016
Phone: (626) 241-1509
Fax: (626) 447-2204
Email: jdavis@childrensoncologygroup.org

PROTOCOL COORDINATOR
Meg Stahlman
Children's Oncology Group
Study Development Office
222 E. Huntington Dr., Suite 100
Monrovia, CA. 91016
Phone: (626) 241-1626
Fax: (626) 445-4334
E-mail: mstahlman@childrensoncologygroup.org

AGENT	NSC#	IND#
CDX-011	763737	128248

IND sponsor for CDX-011: DCTD, NCI

SEE SECTION 15.0 FOR SPECIMEN SHIPPING ADDRESSES

ABSTRACT

The prognosis of patients with recurrent or refractory osteosarcoma remains poor, with 10-year overall survival rates around 20%. Given the continued poor prognosis in this group of patients, novel treatment strategies are needed. There are no standard chemotherapeutic agents or targeted therapies proven to prolong survival in recurrent osteosarcoma. Glycoprotein non-metastatic B (GPNMB) is a type I transmembrane glycoprotein that is normally expressed in a variety of cell types including osteoblasts and osteoclasts, dendritic cells, macrophages, hematopoietic cells, melanocytes and keratinocytes. Aberrant and over expression of GPNMB has been demonstrated in a variety of cancers including osteosarcoma. GPNMB is predominantly expressed on the cell surface of malignant cells, whereas in normal tissues it is generally restricted to intracellular compartments. This unique expression pattern makes GPNMB an attractive target for antibody drug conjugate (ADC) targeted therapy. CDX-011 is an ADC directed against GPNMB. It is comprised of a fully-human IgG2 monoclonal antibody (CR011) conjugated to the potent microtubule inhibitor, monomethyl auristatin E (MMAE), via a protease-sensitive valine-citrulline peptide linker and p-aminobenzoic acid (PABA) spacer. CDX-011 is theorized to exert its antitumor activity by selectively delivering the potent cytotoxin MMAE to GPNMB-expressing tumor cells. Pre-clinical data suggest that CDX-011 may have anti-tumor activity in osteosarcoma. In this Phase 2 study, eligible patients between the ages of 12 months and 50 years with unresected, recurrent or refractory osteosarcoma will receive CDX-011, administered once every 21 days for up to 14 months. Progression free survival and response to therapy will be assessed. In addition, the tolerability and pharmacokinetic (PK) disposition of CDX-011 will be evaluated.

EXPERIMENTAL DESIGN SCHEMA



*Glembatumumab vedotin will be given on Day 1 of each 21-day cycle

Note: Patients who undergo surgical resection of or radiation to any site of measurable disease prior to completion of the 6th cycle of therapy will be taken off protocol therapy.

1.0 GOALS AND OBJECTIVES (SCIENTIFIC AIMS)

1.1 Primary Aims

1.1.1 To estimate whether CDX-011 therapy either improves the disease control rate at 4 months in patients with recurrent measurable osteosarcoma as compared to an historical COG experience or produces an objective response rate in patients without previous eribulin treatment.

1.2 Secondary Aims

1.2.1 To assess the feasibility and toxicity profile of CDX-011 in patients with recurrent osteosarcoma.

1.2.2 To describe the pharmacokinetics of CDX-011 in adolescents and young adults with recurrent osteosarcoma enrolled at COG sites and COG Phase 1 Consortium sites only.

1.2.3 To determine if there is a relationship between tumor GPNMB expression by IHC and response to CDX-011 therapy.

1.2.4 To estimate, in the cohort of patients previously treated with eribulin, the proportion who will experience disease progression during the first 4 months of CDX-011 therapy and the proportion of patients who experience a RECIST-defined complete or partial response.

2.0 BACKGROUND

2.1 Introduction/Rationale for Development

The outcome of patients with newly diagnosed, localized osteosarcoma improved following the addition of multi-agent chemotherapy to complete surgical resection.[1,2] Current results in contemporary cooperative group studies reveal 3-year event-free survival (EFS) ranging between 50-75%.[3-6] Cisplatin[7,8] and doxorubicin[9,10] are the most active agents, and standard chemotherapy includes the use of these two agents alone[5,11] or in combination with high-dose methotrexate[6,12] and/or ifosfamide.[4,12-14] The prognosis is poor for the 30-40% of patients who develop recurrent disease,[15] as well as for those with clinically detectable metastases at the time of initial diagnosis[6,13,16] with 2-year survival rates of 20-30%.[4,6,13,16-21]

The aggregate EFS for patients with recurrent osteosarcoma enrolled on seven closed Phase 2 studies from the COG or its predecessor groups is poor, with an overall 12% EFS at 4 months [95% CI: 6.0%-19%].

Due to the lack of progress seen in treatment of osteosarcoma over the past 25 years and overall poor prognosis for children, adolescents and young adults with recurrent or refractory osteosarcoma, novel treatment strategies are needed.

CDX-011 is an antibody drug conjugate (ADC) directed against Glycoprotein non-metastatic B. The preclinical data that establishes the rationale for proceeding with a Phase 2 evaluation in patients with relapsed or refractory osteosarcoma is described below.

Glycoprotein non-metastatic B (GPNMB) as a therapeutic target: GPNMB (also known as osteoactivin, dendritic cell-heparin integrin ligand, or hematopoietic growth factor inducible neurokinin-1 type) is a type I transmembrane glycoprotein[22-32] that is normally expressed in a variety of cell types including osteoblasts and osteoclasts, dendritic cells, macrophages, hematopoietic cells, melanocytes and keratinocytes.[22-25,28,32-36] While its exact function in normal cells is not fully understood, it is thought to play a role in tissue repair, cellular adhesion, and regulation of cell growth and differentiation.[23,33-38] Aberrant or overexpression of GPNMB has also been demonstrated in a variety of cancers including melanoma, breast cancer, glioma, hepatocellular carcinoma, and osteosarcoma.[23,24,26-29,31,32,39] *In vitro* and *in vivo* studies have demonstrated a role for GPNMB in T cell activation, osteoblast development, osteoclast differentiation and fibroblast differentiation. GPNMB over expression was demonstrated to increase tumor invasiveness and metastasis by promoting angiogenesis and decreasing apoptosis in breast cancer, glioma and hepatocellular carcinoma cell lines.[23,25-30,32,33,40] GPNMB is predominantly expressed on the surface of malignant cells, whereas in normal tissues it is generally restricted to intracellular compartments. This unique expression pattern makes GPNMB an attractive target for ADC targeted therapy.[25,27,32,39-42]

CDX-011: CDX-011 consists of a fully-human IgG2 monoclonal antibody (CR011) conjugated to the potent microtubule inhibitor, monomethyl auristatin E (MMAE) via a protease-sensitive valine-citrulline peptide linker and p-aminobenzoic acid (PABA) spacer. CDX-011 is theorized to exert its antitumor activity by selectively delivering the potent cytotoxin MMAE to GPNMB-expressing tumor cells. After intravenous (IV) administration, CDX-011 binds to GPNMB on the surface of tumor cells. Lysosome internalization of the CDX-011-GPNMB complex leads to the proteolytic cleavage of the valine-citrulline linker and the release of free MMAE into the cytoplasm. Microtubule inhibition by MMAE leads to cell cycle arrest and subsequently tumor cell death.

Antitumor activity of CDX-011 has been demonstrated in xenograft models of melanoma, breast cancer, and osteosarcoma.[23,27,31,34,38,43,44] Additionally, clinical efficacy was observed in adult breast cancer and melanoma trials, making CDX-011 an attractive agent for Phase 2 testing in patients with osteosarcoma. A positive result in this study in addition to the results of other planned studies of CDX-011 will help inform the design of future clinical trials for patients with osteosarcoma.

2.2 Preclinical Studies

The activity of CDX-011 in pediatric tumors was recently investigated through the Pediatric Preclinical Testing Program. GPNMB gene expression was evaluated in a variety of solid tumor and leukemia xenograft models. Given the consistent expression of GPNMB in the osteosarcoma xenografts, the *in vivo* anti-tumor activity was investigated in 6 female CB-17SC mice bearing osteosarcoma. The mice received 2.5 mg/kg of CDX-011 IV weekly for 3 doses, followed by 3 weeks of observation. Complete tumor responses were seen in 3/6 osteosarcoma xenografts. Of the 3 responding xenografts, 2 had the highest levels of GPNMB expression. The lowest GPNMB-expressing osteosarcoma xenograft had minimal response to CDX-011 treatment (Figure 1).[23,45] GPNMB protein expression through immunohistochemistry and by enzyme-linked immunosorbent assay (ELISA) has

also been assessed in human osteosarcoma cell lines. Sixty-seven human osteosarcoma samples were tested and 92.5% of osteosarcoma samples expressed GPNMB. CDX-011 induced cytotoxic effects in 74% of osteosarcoma cell lines and GPNMB protein levels correlated with CDX-011 *in vitro* cytotoxicity.[46]



Figure 1. CDX-011 in vivo objective response activity for osteosarcoma models. Kaplan–Meier curves for EFS (left), median relative tumor volume graphs (center), and individual tumor volume graphs (right) are shown for selected lines. Treated (black lines), statistical significance (P values) of the difference between treated and control groups are included.

2.3 [redacted]

[redacted]

In this trial a tumor sample to test for GPNMB expression by immunohistochemistry (IHC), similar to the previous breast cancer and melanoma clinical trials, will be required. This will allow us to determine if higher levels of GPNMB expression by IHC correlates with tumor response to CDX-011 in osteosarcoma patients.

2.4 Pediatric Studies

There are no data regarding the use of CDX-011 in children. Therefore, this trial will evaluate CDX-011 using a dosage and a schedule of administration that has been shown to be safe in patients with breast cancer and patients with melanoma. In order to assess the tolerability of this dose, 1.88 mg/kg rounded to 1.9 mg/kg, the first six children aged less than 18 years ('younger patients') who enroll on the trial will receive protocol therapy with close toxicity monitoring. Accrual of younger patients will temporarily be suspended after the sixth such patient is enrolled and these patients will be followed to ensure that there are not unanticipated toxicities. Accrual will resume at this dose if fewer than one-third of toxicity evaluable patients experience a DLT. We will continue to monitor closely for toxicities, as we do with all active COG Phase 2 trials. Enrollment of patients 18 years of age or older will continue during the evaluation of toxicity for younger patients. Pharmacokinetic studies are mandatory for the first 6 evaluable patients 14 years of age or less enrolled at any COG member institution. Consent for pharmacokinetic studies for any patient greater than 14 years of age and less than or equal to 21 years of age enrolled at any COG member institution is optional. PK sampling will not be sought for patients who are older than 21 years of age at the time of enrollment.

2.5 Dosing Rationale

CDX-011 will be administered intravenously at a dose of 1.9 mg/kg over 90 minutes on Day 1 of each 3 week cycle. The half-life is 40 hours. This dosing is based on the dosing guidelines used in the Phase 1/2 trial in patients with localized and advanced metastatic breast cancer and stage III or IV melanoma.

3.0 STUDY ENROLLMENT PROCEDURES AND PATIENT ELIGIBILITY

3.1 Study Enrollment

3.1.1 Patient Registration

Prior to enrollment on this study, patients must be assigned a COG patient ID number.

COG sites: This number is obtained via the COG Registry system once authorization for the release of protected health information (PHI) has been obtained. The COG patient ID number is used to identify the patient in all future interactions with COG. If you have problems with the registration, please refer to the online help.

Non-COG sites: Fax the patient registration information (demography) to the Cancer Trials Support Unit (CTSU) registrar at 1-888-691-8039. Sites may notify the registration office of an incoming fax by calling 1888-462-3009; the office hours are 9:00 – 5:30 pm Eastern Time, Monday – Friday. The CTSU registrar will then register the patient within the COG system on behalf of the institution and obtain a COG patient ID number. The CTSU registrar will provide the COG patient ID number to the site which can then enroll the patient in the OPEN system.

A Biopathology Center (BPC) number will be assigned as part of the registration process. Each patient will be assigned only one BPC number per COG Patient ID. For additional information about the labeling of specimens please refer to the Pathology and/or Biology Guidelines in this protocol.

Please see Appendix I for detailed CTEP Registration Procedures for Investigators and Associates, and CTSU Registration Procedures including: how to download site registration documents; requirements for site registration, submission of regulatory documents and how to check your site's registration status.

3.1.2 IRB Approval

Sites must obtain IRB/REB approval for this protocol and submit IRB/REB approval and supporting documentation to the CTSU Regulatory Office before they can be approved to enroll patients. Allow 3 business days for processing. The submission must include a fax coversheet (or optional CTSU IRB Transmittal Sheet) and the IRB approval document(s). The CTSU IRB Certification Form may be submitted in lieu of the signed IRB approval letter. All CTSU forms can be located on the CTSU web page (https://www.ctsu.org). Any other regulatory documents needed for access to the study enrollment screens will be listed for the study on the CTSU Member's Website under the RSS Tab.

IRB/REB approval documents may be faxed (1-215-569-0206),
E-mailed (CTSURegulatory@ctsu.coccg.org) or mailed to the CTSU Regulatory office.

When a site has a pending patient enrollment within the next 24 hours, this is considered a "Time of Need" registration. For Time of Need registrations, in addition to marking your submissions as 'URGENT' and faxing the regulatory documents, call the CTSU Regulatory Helpdesk at: 1-866-651-CTSU. For general (non-regulatory) questions call the CTSU General Helpdesk at: 1-888-823-5923.

Study centers can check the status of their registration packets by querying the Regulatory Support System (RSS) site registration status page of the CTSU members' web site by entering credentials at https://www.ctsu.org. For sites under the CIRB initiative, IRB data will automatically load to RSS.

Note: Sites participating on the NCI CIRB initiative and accepting CIRB approval for the study are not required to submit separate IRB approval documentation to the CTSU Regulatory Office for initial, continuing or amendment review. This information will be provided to the CTSU Regulatory Office from the CIRB at the time the site's Signatory Institution accepts the CIRB approval. The Signatory site may be contacted by the CTSU Regulatory Office or asked to complete information verifying the participating institutions on the study. Other site registration requirements (ie, laboratory certifications, protocol-specific training certifications, or modality credentialing) must be submitted to the CTSU Regulatory Office or compliance communicated per protocol instructions.

3.1.3 Reservation Requirements

Prior to obtaining informed consent and enrolling a patient, a reservation must be made following the steps below. Reservations may be obtained 24 hours a day through the Oncology Patient Enrollment Network (OPEN) system.

Patient enrollment for this study will be facilitated using the Slot-Reservation System in conjunction with the Registration system in OPEN. Prior to discussing protocol entry with the patient, site staff must use the CTSU OPEN Slot

Reservation System to ensure that a slot on the protocol is available for the patient. Once a slot-reservation confirmation is obtained, site staff may then proceed to enroll the patient to this study.

If the study is active, a reservation can be made by following the steps below:

1) Log in to https://open.ctsu.org/open/ using your CTEP IAM user name and password.
2) In order to make a reservation, the patient must have an OPEN patient number. Click on the 'Slot Reservation' tab to create an OPEN patient number, under 'Patients'.
3) Using the OPEN patient number '**RESERVE'** a slot for that patient.
4) On the 'Create Slot Reservation' page, select the Protocol Number, enter the COG Patient ID, and choose the required stratum (if applicable) in order to obtain a reservation.

   Refer to the 'SITE – Slot Reservation Quick Reference' guide posted under the 'Help' tab in OPEN for detailed instructions: https://www.ctsu.org/readfile.aspx?fname=OPEN/OPEN_SlotReservation_QuickReference_SiteUserGuide_102612.pdf&ftype=PDF

3.1.4 Study Enrollment

Patient enrollment will be facilitated using the Oncology Patient Enrollment Network (OPEN). OPEN is a web-based registration system available on a 24/7 basis. To access OPEN, the site user must have an active CTEP-IAM account (check at < https://eapps-ctep.nci.nih.gov/iam/index.jsp >) and a 'Registrar' role on either the lead protocol organization (LPO) or participating organization roster.

All site staff will use OPEN to enroll patients to this study. It is integrated with the CTSU Enterprise System for regulatory and roster data and, upon enrollment, initializes the patient position in the Rave database. OPEN can be accessed at https://open.ctsu.org or from the OPEN tab on the CTSU members' side of the website at https://www.ctsu.org.

Prior to accessing OPEN, site staff should verify the following:

- All eligibility criteria have been met within the protocol stated timeframes.
- All patients have signed an appropriate consent form and HIPAA authorization form (if applicable).

Note: The OPEN system will provide the site with a printable confirmation of registration and treatment information. Please print this confirmation for your records.

Further instructional information is provided on the CTSU members' web site OPEN tab or within the OPEN URL (https://open.ctsu.org). For any additional questions contact the CTSU Help Desk at 1-888-823-5923 or ctsucontact@westat.com.

3.1.5 Timing

Patients must be enrolled before treatment begins. The date protocol therapy is projected to start must be no later than **seven (7)** business days after the date of study enrollment. **Patients who are started on protocol therapy on a Phase 2 study prior to study enrollment will be considered ineligible**.

All clinical and laboratory studies to determine eligibility must be performed within 7 days prior to enrollment unless otherwise indicated in the eligibility section below.

Institutions are advised to plan ahead to ensure adequate and timely delivery of the investigational agent (see Section 6.1 for details).

3.1.6 Participation in Biology Studies

In order to minimize the potential for non-compliance once enrolled, patients/guardians must be made aware that some of the biology research studies are mandatory and understand that a number of non-standard blood samples will be required.

3.1.7 Inclusion of Women and Minorities

Both men and women of all races and ethnic groups are eligible for this study.

3.2 Patient Eligibility Criteria

Important note: The eligibility criteria listed below are interpreted literally and cannot be waived. All clinical and laboratory data required for determining eligibility of a patient enrolled on this trial must be available in the patient's medical/research record which will serve as the source document for verification at the time of audit.

All clinical and laboratory studies to determine eligibility must be performed within 7 days prior to enrollment unless otherwise indicated. Laboratory values used to assess eligibility must be no older than seven (7) days at the start of therapy. Laboratory tests need not be repeated if therapy starts within seven (7) days of obtaining labs to assess eligibility. If a post-enrollment lab value is outside the limits of eligibility, or laboratory values are > 7 days old, then the following laboratory evaluations must be re-checked within 48 hours prior to initiating therapy: CBC with differential, bilirubin, ALT (SGPT) and serum creatinine. If the recheck is outside the limits of eligibility, the patient may not receive protocol therapy and will be considered off protocol therapy. Imaging studies, if applicable, must be obtained within 2 weeks prior to start of protocol therapy (repeat the tumor imaging if necessary).

See Section 4.2.1 for required studies to be obtained prior to starting protocol therapy.

3.2.1 Age

Patients must be equal to or greater than 12 years of age but less than 50 years of age at the time of enrollment.

3.2.2 Diagnosis

3.2.2.1 Patients must have had histologic verification of osteosarcoma at original diagnosis or relapse.

3.2.2.2 Patients must have measurable disease according to RECIST 1.1 (see Section 10.2), and have relapsed or become refractory to conventional therapy.

3.2.3 Specimen Submission

Patient must have archival tumor specimen available for submission (see Section 15.1).

3.2.4 Performance Level

Patients must have a performance status corresponding to ECOG scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients ≤ 16 years of age. See https://members.childrensoncologygroup.org/prot/reference_materials.asp under Standard Sections for Protocols.

3.2.5 Prior Therapy

Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

a. Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study (4 weeks if prior nitrosourea).

b. Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent.

c. Radiation therapy (RT): ≥ 2 weeks for local palliative RT (small port); ≥ 6 months must have elapsed if prior craniospinal RT or if ≥ 50% radiation of pelvis; ≥ 6 weeks must have elapsed if other substantial BM radiation.

d. Monoclonal antibodies: Must not have received any monoclonal based therapies within 4 weeks, and all other immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) within 2 weeks, prior to study enrollment.

Please see Section 4.1.1 for the concomitant therapy restrictions for patients during treatment.

3.2.6 Organ Function Requirements

3.2.6.1 Adequate Bone Marrow Function Defined As:

- Peripheral absolute neutrophil count (ANC) ≥ 1000/μL
- Platelet count ≥ 75,000/μL (transfusion independent)
- Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)

3.2.6.2 Adequate Renal Function Defined As:

- Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m^2 or

- A serum creatinine based on age/gender as follows:

Age	Maximum Serum Creatinine (mg/dL)	
	Male	Female
1 to < 2 years	0.6	0.6
2 to < 6 years	0.8	0.8
6 to < 10 years	1	1
10 to < 13 years	1.2	1.2
13 to < 16 years	1.5	1.4
≥ 16 years	1.7	1.4

The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR[50] utilizing child length and stature data published by the CDC.

3.2.6.3 Adequate Liver Function Defined As:
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and
- SGOT (AST) or SGPT (ALT) < 110 U/L. For the purposes of this study the ULN for SGPT is defined as 45 U/L.
- Serum albumin > 2 g/dL

3.2.6.4 Adequate Cardiac Function Defined As:
- Shortening fraction of ≥ 27% by echocardiogram, or
- Ejection fraction of ≥ 50% by radionuclide angiogram.

3.2.7 Exclusion Criteria

3.2.7.1 Patients with > Grade 2 neuropathy according to the Modified ("Balis") Pediatric Scale (see Section 5.2.4) of Peripheral Neuropathies will be excluded except in cases in which neuropathy is secondary to prior surgery.

3.2.7.2 Patients who have previously received CDX-011 (CR011-vcMMAE; CDX-011) or other MMAE-containing agents.

3.2.7.3 Patients who have received other investigational drugs within 2 weeks or 5 half-lives (whichever is longer) prior to study enrollment.

3.2.7.4 Patients with a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin. Compounds of similar composition include Auristatin PHE as an anti-fungal agent, Auristatin PE (TZT-1027, Soblidotin, NSC-654663) as an anti-tumor agent and symplostatin 1 as an anti-tumor agent.

3.2.7.5 Patients with known central nervous system metastasis are not eligible.

3.2.7.6 Patients who have had major surgery within 2 weeks prior to enrollment are not eligible. Procedures such as placement of a central vascular catheter, or limited tumor biopsy, are not considered major surgery.

3.2.7.7 Pregnancy and Breast Feeding

3.2.7.7.1 Female patients who are pregnant are ineligible since there is yet no available information regarding human fetal or teratogenic toxicities.

3.2.7.7.2 Lactating females are not eligible unless they have agreed not to breastfeed their infants.

3.2.7.7.3 Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.

3.2.7.7.4 Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and for 2 months after the end of study treatment.

3.2.8 Regulatory Requirements

3.2.8.1 All patients and/or their parents or legal guardians must sign a written informed consent.

3.2.8.2 All institutional, FDA, and NCI requirements for human studies must be met.

4.0 TREATMENT PROGRAM

Timing of protocol therapy administration, response assessment studies, and surgical interventions are based on schedules derived from the experimental design or on established standards of care. Minor unavoidable departures (up to 72 hours) from protocol directed therapy and/or disease evaluations (and up to 1 week for surgery) for valid clinical, patient and family logistical, or facility, procedure and/or anesthesia scheduling issues are acceptable (except where explicitly prohibited within the protocol).

4.1 Overview of Treatment Plan

This is a single arm Phase 2 study to evaluate the use of CDX-011, an ADC directed against GPNMB. All subjects will receive CDX-011 at 1.9 mg/kg intravenously over 90 minutes every 21 days. Treatment will be discontinued if there is evidence of progressive disease or drug related toxicity that requires removal from therapy, as defined in Section 5.0. Therapy may otherwise continue for a maximum duration of 14 months or ~18 cycles, whichever occurs first. Radiographic imaging assessments of disease status obtained after Cycles 2, 4 and 6 will be compared to imaging done just prior to initiating therapy. For those patients remaining on protocol therapy, subsequent imaging studies for assessment of disease status will occur after every 3rd cycle.

Other therapy: Although not encouraged, subjects who achieve a partial response after Cycle 2 that is confirmed after Cycle 6 will be allowed to undergo resection of sites of disease or radiation and remain on protocol therapy. Therapy will be held during surgery and resumed when recovered from surgery but at least 2 weeks after surgery. CDX-011 therapy will be held during radiation and may be resumed upon completion of the radiation treatment course. If the patient has not recovered from surgery within 6 weeks the patient will go off protocol therapy. Surgery or radiation performed on any site of measurable disease before the end of the sixth cycle will render the patient inevaluable for disease control assessment and they will be removed from protocol therapy.

4.1.1 Concomitant Therapy

4.1.1.1 CYP3A4 inducers and inhibitors

The use of the following medications should be discontinued prior to initiation of protocol therapy and should be avoided during protocol therapy if reasonable alternatives exist. This is not an inclusive list; please refer to other resources such as http://medicine.iupui.edu/clinpharm/ddis/table.aspx or other frequently updated medical reference for additional information.

CYP3A4 substrates	Strong Inhibitors*	Moderate Inhibitors	Weak Inhibitors	Inducers
alfentanil	atazanavir	aprepitant	amiodarone	armodafinil
amiodarone	boceprevir	atazanavir	ciprofloxacin	barbiturates
aprepitant	clarithromycin	cimetidine	doxycycline	bosentan
benzodiazepines	cobicistat	crizotinib	mifepristone	carbamazepine
bortezomib	conivaptan	cyclosporine	metronidazole	deferasirox
brentuximab	delavirdine	desipramine	nicardipine	efavirenz
budesonide	fosamprenavir	diltiazem	propofol	etravirine
calcium channel blockers	indinavir	erythromycin	quinidine	fosphenytoin

cisapride citalopram/escitalopram glucocorticoids crizotinib cyclosporine cyclophosphamide dapsone dasatinib dihydroergotamine docetaxel doxorubicin ergotamine erlotinib esomeprazole estrogens etoposide fentanyl fosaprepitant gefitinib haloperidol HIV antiretrovirals HMG Co-A inhibitors ifosfamide imatinib irinotecan itraconazole ketoconazole lansoprazole lapatinib losartan lovastatin macrolide antibiotics medroxyprogesterone methadone midazolam modafinil monteleukast nefazodone nilotinib omeprazole ondansetron paclitaxel pazopanib quinidine sildenafil sirolimus sunitinib tacrolimus terfenadine telaprevir tamoxifen	itraconazole ketoconazole nefazodone nelfinavir posaconazole ritonavir saquinavir telaprevir telithromycin voriconazole	fluconazole fluvoxamine fosaprepitant grapefruit grapefruit juice imatinib norfloxacin tetracycline verapamil	sertraline tacrolimus	glucocorticoids modafinil nafcillin nevirapine oxcarbazepine phenobarbital phenytoin pioglitazone primidone rifabutin rifampin rifapentin ritonavir St. John's wort topiramate

temsirolimus teniposide trimethoprim vinca alkaloids zolpidem				

* Certain fruits and fruit juices (star fruit, Seville oranges, pomegranate) may inhibit CYP 3A4 isozyme, however, the degree of that inhibition is unknown.

4.1.1.2 The administration of P-gp inhibitors should be avoided while the patient is receiving protocol therapy due to risk of increased exposure to MMAE.

4.1.1.3 No other antineoplastic agents may be given while the patient is receiving protocol therapy.

4.1.1.4 Growth factors that support white cell number or function should only be administered for culture proven bacteremia, invasive fungal infection, or if there was a Grade 4 ANC of > 7 days duration in a previous cycle or a delay of > 14 days between cycles for neutropenia.

For COG Supportive Care Guidelines see: https://members.childrensoncologygroup.org/prot/reference_materials.asp under Standard Sections for Protocols.

4.2 Therapy Delivery Map – CDX-011

4.2.1 Therapy Delivery Map – All Cycles of CDX-011 Each cycle lasts 3 weeks (21 days). Treatment may continue for up to 14 months or 18 cycles, whichever occurs first. One cycle of treatment is described in this TDM. This TDM is on 2 pages. Use a copy of this page once for each cycle (please note cycle number below).	_____ Patient COG ID number _____ DOB

Begin CDX-011 therapy only when ANC ≥ 1000/µL; Platelets ≥ 75,000/µL (transfusion independent); Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed); Cr clearance or radioisotope GFR ≥ 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender as per Section 4.2.3; Total bilirubin ≤ 1.5 x ULN for age; SGOT (AST) or SGPT (ALT) ≤ 110 U/L, and Serum albumin > 2 g/dL.

DRUG	ROUTE	DOSAGE	DAY	IMPORTANT NOTES
CDX-011 (glembatumumab vedotin) IND# 128248	IV over 90 minutes	1.9 mg/kg/dose	Day 1	Recalculate the dose prior to each infusion. Round dose to the nearest 1 mg. See Section 4.2.3 for complete details.

Enter Cycle #: _____ Ht _____cm Wt _____kg BSA _____m^2

Date Due	Date Given	Day	CDX-011 ____mg	Studies
			Enter calculated dose above and actual dose administered below	
		1	____mg	a-l
		8*		(a-f)*
		21		g, h, i

Start the next cycle on Day 22 or as soon as starting criteria are met, whichever occurs later. Treatment should continue up to 14 months (or 18 cycles, whichever occurs first) in the absence of disease progression or unacceptable toxicity. If disease progression or unacceptable toxicity occurs, the patient will be taken off protocol therapy.
Note: Patients who receive surgery or radiation on any site of measurable disease prior to completion of the 6th cycle of therapy will be taken off protocol therapy.

* Cycle 1 only

See Section 5.0 for Dose Modifications for Toxicities and the COG Member website for Supportive Care Guidelines.

All Cycles

4.2.2 Required Observations Prior to Cycle 1 and During All Cycles

All baseline studies must be performed prior to starting protocol therapy unless otherwise indicated below. For Cycle 1 only, observations a-f can be performed up to 7 days before the start of therapy and imaging studies may be obtained within 2 weeks prior to the start of therapy.

a. Hx/PE/Wt /Ht. Prior to each cycle and on Day 8 of Cycle 1.

b. CBC/diff/platelets. Prior to each cycle and on Day 8 of Cycle 1.

c. Bilirubin & Creatinine. Prior to each cycle and on Day 8 of Cycle 1.

d. Electrolytes, BUN, Ca^{++}, PO_4, Mg^{++}. Prior to each cycle and on Day 8 of Cycle 1.

e. AST, ALT, albumin. Prior to each cycle and on Day 8 of Cycle 1.

f. Neurologic evaluation. Prior to each cycle and on Day 8 of Cycle 1. Assess for NCI CTCAE > Grade 2 neuropathy.

g. CT chest. Prior to Cycle 1 and following Cycles 2, 4, 6 and every 3rd cycle thereafter.

h. Tumor disease evaluation. Prior to Cycle 1 and following Cycles 2, 4, 6, and every 3rd cycle thereafter. Evaluations should include CT or MRI of all lesions meeting eligibility criteria. Use the same imaging modality for all disease evaluations. Patients who had a RECIST response (CR or PR) at Cycle 6 imaging evaluation are required to have a confirmatory scan following Cycle 8. For patients who undergo a surgical resection following Cycle 6, either a CT scan or MRI post-surgery to establish a new baseline is strongly recommended prior to re-initiating CDX-011 therapy. See Section 16.0 for details.

i. ^{18}FDG PET or Bone Scan. Prior to Cycle 1 and following Cycles 2, 4, 6, and every 3rd cycle thereafter. ^{18}FDG PET or bone scan is required at baseline. ^{18}FDG PET scan is an optional study, but if completed then a bone scan is not necessary. It is recommended to obtain MRI or CT scan of any lesion positive on bone or ^{18}FDG PET scan. Bone or ^{18}FDG PET scan is required to assess for new disease after Cycles 2, 4 and 6. Further bone scan or ^{18}FDG PET should be completed as clinically indicated at investigator discretion. For consistency, investigators are encouraged to utilize the same modality used at baseline to follow positive lesions that are identified with ^{18}FDG PET or bone scan. See Section 16.0 for details.

j. Pharmacokinetics. Cycle 1 only, Day 1 pre-dose, end of infusion, 1, 2, 4, 8 and 24 (+/- 4 hours) hours post infusion, 4 days (+/- 1 day) post infusion, 7 and 21 days post infusion. Required for the first 6 evaluable patients ≤ 14 years of age enrolled at COG sites. Optional for patients > 14 years of age and ≤ 21 years of age enrolled at COG sites. See Section 15.2 for details.

k. Tumor GPNMB expression (required). Submission of a formalin-fixed, paraffin-embedded (FFPE) sample of tumor tissue (block or 10 slides) from the most recent surgery (preferred) or from any previous biopsy or resection is mandatory within 4 weeks of enrollment. See Section 15.1 for details.

l. Pregnancy test. Prior to Cycle 1. Female patients of childbearing potential require a negative pregnancy test prior to starting treatment; sexually active patients must use an acceptable method of birth control.

This listing only includes evaluations necessary to answer the primary and secondary aims. OBTAIN OTHER STUDIES AS REQUIRED FOR GOOD CLINICAL CARE.

Comments (Include any held doses, or dose modifications)

All Cycles

All Cycles

4.2.3 Therapy During Cycle 1 and Subsequent Cycles

One cycle of CDX-011 treatment is described below. A cycle may be repeated every 21 days (3 weeks) if the patient has at least stable disease and has again met laboratory parameters as defined in the eligibility section, and detailed below.

CDX-011 (glembatumumab vedotin): Intravenously over 90 minutes
Day: 1
Dose: **1.9 mg/kg/dose.** Round doses to the nearest 1 mg.
Actual body weight will be recorded and used to calculate dose prior to each infusion. CDX-011 is to be diluted with D5W and administered using a 0.22 µm low protein binding in-line filter. Patient should receive post-infusion flush with appropriate volume of D5W administered at the same rate as CDX-011 infusion.

Note: Premedication is not required, but may be used as clinically indicated.

Monitoring during CDX-011 infusion:

- Vital signs should be assessed every 15 minutes for the first hour of the infusion, followed by every 30 minute assessment for the remainder of the infusion and post-infusion flush. More frequent assessment may be required based on the patient's clinical condition.

Criteria to start each cycle



See Section 5.0 for Dose Modifications based on Toxicities.

5.0 DOSE MODIFICATIONS FOR TOXICITIES

5.1 Definition of Toxicities

NOTE: Any suspected or confirmed dose-limiting toxicity should be reported to the Study Chair within 24 hours of site knowledge of its occurrence.

5.1.1 Definition of Dose-Limiting Toxicity (DLT)

DLT will be defined as any of the following events that are possibly, probably or definitely attributable to protocol therapy.

Note: Dose limiting hematological and non-hematological toxicities are defined differently.

5.1.1.1 Hematological Dose Limiting Toxicity

- Grade 4 neutropenia for > 7 days
- Grade 4 febrile neutropenia
- Platelet count < 25,000/μL on 2 separate days, or requiring a platelet transfusion on 2 separate days, within a 7 day period
- Myelosuppression that causes a delay of > 14 days between treatment cycles.

5.1.1.2 Non-Hematological Dose-Limiting Toxicity

- Any Grade 3 or greater non-hematological toxicity, except for the following:
  - Grade 3 nausea and/or vomiting of < 3 days duration
  - Grade 3 or 4 fever < 5 days duration
  - Grade 3 infection < 5 days duration
  - Grade 3 rash < 5 days duration
  - Grade 3 pruritis < 5 days duration
  - Grade 3 fatigue < 5 days duration
  - Grade 3 non-hematologic laboratory abnormalities that resolve within 14 days to Grade 1, or to initial eligibility criteria, or to baseline (if the patient entered the study with existing toxicity). Note: for the purposes of this study the ULN for SGPT (ALT) is defined as 45 U/L.
  - Grade 3 infusion-related reactions < 24 hours duration (see Section 5.2.3)
  - Grade 3 hypophosphatemia, hypokalemia, hypocalcemia, or hypomagnesemia responsive to oral supplementation.

- Any Grade 2 non-hematological toxicity that persists for ≥ 7 days and is considered sufficiently medically significant or sufficiently intolerable by patients that it requires treatment interruption will also be considered a DLT.

5.2 Dose Modifications for Adverse Events

The Study Chair must be notified of any use of myeloid growth factor for hematologic toxicity and of any other dosage modification described below.



[redacted]



[redacted]





Modified ("Balis") Pediatric Scale of Peripheral Neuropathies

Peripheral Motor Neuropathy:

- Grade 1: Subjective weakness, but no deficits detected on neurological exam, other than abnormal deep tendon reflexes.
- Grade 2: Weakness that alters fine motor skills (buttoning shirt, coloring, writing or drawing, using eating utensils) or gait without abrogating ability to perform these tasks.
- Grade 3: Unable to perform fine motor tasks (buttoning shirt, coloring, writing or drawing, using eating utensils) or unable to ambulate without assistance.
- Grade 4: Paralysis.

Peripheral Sensory Neuropathy:

- Grade 1: Paresthesias, pain, or numbness that do not require treatment or interfere with extremity function.
- Grade 2: Paresthesias, pain, or numbness that are controlled by non-narcotic medications (without causing loss of function), or alteration of fine motor skills (buttoning shirt, writing or drawing, using eating utensils) or gait, without abrogating ability to perform these tasks.
- Grade 3: Paresthesias or pain that are controlled by narcotics, or interfere with extremity function (gait, fine motor skills as outlined above), or quality of life (loss of sleep, ability to perform normal activities severely impaired).
- Grade 4: Complete loss of sensation, or pain that is not controlled by narcotics.



6.0 DRUG INFORMATION

6.1 CDX-011

(GLEMBATUMUMAB VEDOTIN, CR011-vcMMAE) NSC# 763737, IND# 128248

(09/01/16)

Source and Pharmacology:

CDX-011 is an antibody-drug conjugate (ADC) comprised of a fully-human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the tubulin-binding cytotoxic agent monomethylauristatin E (MMAE) via a protease-sensitive valine-citrulline linker and p-aminobenzoic acid (PABA) spacer. The average MMAE: antibody molar ratio is approximately 4.5:1. The antibody is manufactured by Chinese Hamster Ovary (CHO) cell culture, and the drug-linker combination vcMMAE is manufactured by chemical synthesis.

The proposed mechanism of action of CDX-011 is as follows: After the ADC binds to GPNMB on tumor cells, the complex is internalized and MMAE is released via proteolytic cleavage of the valine-citrulline linker in a lysosomal compartment. Tumor cell death occurs as a result of microtubule inhibition by MMAE with resultant cell cycle arrest.

Pharmacokinetics

[redacted]

Toxicity:

Comprehensive Adverse Events and Potential Risks list (CAEPR) for CDX-011 (glembatumumab vedotin, NSC 763737)

The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of reported and/or potential adverse events (AE) associated with an agent using a uniform presentation of events by body system. In addition to the comprehensive list, a subset, the Specific Protocol Exceptions to Expedited Reporting (SPEER), appears in a separate column and is identified with bold and italicized text. This subset of AEs (SPEER) is a list of events that are protocol specific exceptions to expedited reporting to NCI (except as noted below). Refer to the 'CTEP, NCI Guidelines: Adverse Event Reporting Requirements' http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf for further clarification. *Frequency is provided based on 255 patients.* Below is the CAEPR for CDX-011 (glembatumumab vedotin).

NOTE: Report AEs on the SPEER **ONLY IF** they exceed the grade noted in parentheses next to the AE in the SPEER. If this CAEPR is part of a combination protocol using multiple investigational agents and has an AE listed on different SPEERs, use the lower of the grades to determine if expedited reporting is required.

[redacted]

[redacted]

[redacted]

Guidelines for Administration:
See Treatment and Dose Modification sections of the protocol for complete details. CDX-011 is diluted with D5W and administered as a 90-minute IV infusion using a 0.22 μm low protein binding in-line filter. Patient should receive post-infusion flush with appropriate volume of D5W administered at the same rate as CDX-011 infusion.

Supplier:
CDX-011 is supplied by Celldex Therapeutics and distributed by the Division of Cancer Treatment and Diagnosis (DCTD), NCI.

Obtaining the Agent

Agent Ordering

To comply with the timing requirement for study enrollment (Section 3.1.5), participating institutions are advised to plan ahead to ensure adequate and timely delivery of the investigational agent. Participating institutions may have to use their express courier account for overnight shipping when ordering the agent.

NCI supplied agent may be requested by the Principal Investigator (or their authorized designee) at each participating institution. Pharmaceutical Management Branch (PMB) policy requires that agent be shipped directly to the institution where the patient is to be treated. PMB does not permit the transfer of agents between institutions (unless prior approval from PMB is obtained). The CTEP assigned protocol number must be used for ordering all CTEP supplied investigational agents. The responsible investigator at each participating institution must be registered with CTEP, DCTD through an annual submission of FDA form 1572 (Statement of Investigator), Curriculum Vitae, Supplemental Investigator Data Form (IDF), and Financial Disclosure Form (FDF). If there are several participating investigators at one institution, CTEP supplied investigational agents for the study should be ordered under the name of one lead investigator at that institution.

Active CTEP-registered investigators and investigator-designated shipping designees and ordering designees must submit agent requests through the PMB Online Agent Order Processing (OAOP) application https://eapps-ctep.nci.nih.gov/OAOP/pages/login.jspx. Access to OAOP requires the establishment of a CTEP Identity and Access Management (IAM) account https://eapps-ctep.nci.nih.gov/iam/ and the maintenance of an "active" account status and a "current" password. For questions about drug orders, transfers, returns, or accountability, call (240) 276-6575 Monday through Friday between 8:30 am and 4:30 pm (ET) or email PMBAfterHours@mail.nih.gov anytime.

Agent Accountability

Agent Inventory Records:

The investigator, or a responsible party designated by the investigator, must maintain a careful record of the inventory and disposition of all agents received from DCTD using the NCI Drug Accountability Record Form (DARF). See the CTEP home page at http://ctep.cancer.gov for the Procedures for Drug Accountability and Storage and to obtain a copy of the DARF and Clinical Drug Request form.

Agent Returns:

Investigators/Designees must return unused DCTD supplied investigational agent to the NCI clinical repository as soon as possible when: the agent is no longer required because the study is completed or discontinued and the agent cannot be transferred to another DCTD sponsored protocol; the agent is outdated or the agent is damaged or unfit for use. Regulations require that all agents received from the DCTD, NCI be returned to the DCTD, NCI for accountability and disposition. Return only unused vials/bottles. Do NOT return opened or partially used vials/bottles unless specifically requested otherwise in the protocol. See the CTEP web site for Policy and Guidelines for Investigational agent Returns at: http://ctep.cancer.gov/protocolDevelopment/default.htm#agents_drugs. The appropriate forms may be obtained at: http://ctep.cancer.gov/forms/docs/return_form.pdf.

7.0 EVALUATIONS/MATERIAL AND DATA TO BE ACCESSIONED

Timing of protocol therapy administration, response assessment studies, and surgical interventions are based on schedules derived from the experimental design or on established standards of care. Minor unavoidable departures (up to 72 hours) from protocol directed therapy and/or disease evaluations (and up to 1 week for surgery) for valid clinical, patient and family logistical, or facility, procedure and/or anesthesia scheduling issues are acceptable (except where explicitly prohibited within the protocol).

7.1 End of Therapy & Follow-up

STUDIES TO BE OBTAINED	End of Therapy
History	X
Physical exam with VS	X
Performance status	X
CBC, differential, platelets	X
Electrolytes including Ca^{++}, PO_4, Mg^{++}	X
Creatinine, SGPT, bilirubin	X
Total protein/albumin	X
Tumor disease evaluation (see Section 16.0)	X

See COG Late Effects Guidelines for recommended post treatment follow-up: http://www.survivorshipguidelines.org/

Note: Follow-up data must be submitted in accordance with the Case Report Forms (CRFs) schedule.

8.0 CRITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF STUDY CRITERIA

8.1 Criteria for Removal from Protocol Therapy

a) Progressive disease.
b) Unacceptable toxicity due to protocol therapy (see Section 5.0).
c) Refusal of further protocol therapy by patient/parent/guardian.
d) Completion of planned therapy.
e) Physician determines it is in patient's best interest.
f) Development of a second malignancy.
g) Repeat eligibility studies (if required) are outside the parameters required for eligibility (see Section 3.2).
h) Surgery or radiation performed on any site of measurable disease before the end of the 6th cycle.
i) Failure to recover from surgery within 6 weeks.
j) Pregnancy.

Patients who are off protocol therapy are to be followed until they meet the criteria for Off Study (see below). Follow-up data will be required unless patient is taken off study.

8.2 **Off Study Criteria**

a) Death.
b) Lost to follow-up.
c) Patient enrollment onto another COG study with tumor therapeutic intent (eg, at recurrence).
d) Withdrawal of consent for any further data submission.
e) The fifth anniversary of the date the patient was enrolled on this study.

9.0 STATISTICAL CONSIDERATIONS

9.1 **Sample Size and Study Duration**

A review of enrollment on COG single-agent Phase 2 studies demonstrates that approximately 1.8 patients per month will potentially be eligible for AOST1521. A maximum of 29 outcome evaluable patients will be required for the evaluation of CDX-011 amongst patients without prior treatment with eribulin. Eribulin has not been used as a component of therapy for newly diagnosed patients in pediatric protocols and there has been only one COG study of that agent for patients with recurrent disease. As such, we expected no more than 15% of patients who are eligible for this study to have received eribulin as part of therapy prior to potential enrollment on this study. Providing for possible ineligible and inevaluable patients, the maximum enrollment will be 38 patients.

With these entry rates, the probability we will accrue at least 38 patients in 24 months is 80% and the corresponding probability for 30 months is in excess of 99%. The study will likely require 2 to 2.5 years to enroll sufficient patients. A maximum of 38 patients is anticipated.

9.2 **Study Design**

Feasibility Cohort: The first six (6) younger patients (< 18 years of age) who are evaluable for toxicity will be considered as the feasibility cohort. All such patients will be assigned to receive 1.9 mg/kg/dose. Enrollment to this cohort will not be segregated by prior treatment with eribulin. Study accrual will be suspended after the sixth patient is enrolled; enrollment of patients 18 years of age or older will continue regardless of the result in the feasibility cohort. If dose limiting toxicity (DLT) during the first cycle of therapy occurs in one or fewer evaluable patients then the trial accrual will proceed as outlined below. Patients who are enrolled in the toxicity cohort who receive the "feasible" dose of CDX-011 will be considered in the outcome evaluation rules presented below for the relevant patient stratum as it relates to prior eribulin exposure.

Patients will be enrolled in two stages. In the first stage, 19 disease control and RECIST response evaluable patients will be enrolled. Each patient will be evaluated for both outcome measures: (1) disease control success; and (2) RECIST response (CR or PR *v.* not CR or PR). The decision rule for the two stage study design is summarized as:

Stage	Number of Patients Enrolled in Stage	Cumulative Response Results	Decision
I	19	4 or fewer disease control successes	Terminate the trial with the conclusion that Glembatumumab

		and 1 or fewer RECIST responders	Vedotin is not associated with sufficient activity for further single agent investigation
		5 or more disease control success or 2 or more RECIST responders	Continue to stage II
II	10	8 or fewer disease control successes and 4 or fewer RECIST responders	Terminate the trial with the conclusion that Glembatumumab Vedotin is not associated with sufficient activity for further single agent investigation
		9 or more disease control successes or 5 or more RECIST responders	Terminate the trial with the conclusion that Glembatumumab Vedotin is associated with sufficient activity for further single agent investigation

Design Characteristics: Each patient enrolled will be evaluated for: (1) complete or partial response as defined by the RECIST criteria where the first evaluation of CR or PR is made at or before the end of the sixth cycle of study therapy (denoted as R below); or (2) stable disease after four months of therapy or at the end of the sixth cycle, whichever occurs first (denoted as S below). We will not be interested in promoting the agent for further investigation if the probability of response in any particular individual is less than or equal to 0.05 (P(R)≤0.05) and the probability of remaining analytic event free in any particular individual is less than or equal to 0.20 (P(S)≤0.20). We will be interested in promoting the agent for further investigation if the probability of response in any particular individual is at least 0.22 (P(R)≥0.22) **or** the probability of remaining analytic event free in any particular individual is at least 0.42 (P(S)≥0.42).

For the calculations below, it is assumed $\Pr(S \mid R) = 0.90$.

The statistical characteristics of this design are:

Probability of four month disease control	Probability of RECIST response	Probability of Stopping After Stage 1 (and concluding the drug is ineffective)	Probability of Concluding the Drug is Ineffective at the Conclusion of the Trial	Probability of Concluding the Drug is Effective at the Conclusion of the Trial
0.20	0.05	0.56	0.89	0.11
0.42	0.22	0.014	0.05	0.95
0.42	0.05	0.044	0.096	0.904
0.20	0.22	0.056	0.21	0.79

Prior Treatment with Eribulin: As noted in Section 9.1, we expect no more than 15% of patients will have been treated with eribulin prior to enrollment on AOST1521. Patients will be evaluated for S and R as described above. Enrollment to this stratum will be terminated when we can determine there are sufficient patients to fully evaluate the efficacy of CDX-011 in the stratum of patients without prior eribulin therapy. If 19 patients with prior eribulin therapy are enrolled, the staged design described above for patients without prior eribulin therapy will be applied to this stratum.

9.3 Methods of Analysis for Pharmacokinetics (Aim 1.2.2)

Data from all patients who provide samples for pharmacokinetic analysis will be aggregated. The sample mean and variance of the AUC, clearance and half-life will be calculated. No formal statistical testing will be done.

Pharmacokinetic studies are mandatory for the first 6 evaluable patients 14 years of age or less who are enrolled at an institution which is a member of COG. Consent for pharmacokinetic studies for any patient greater than 14 years of age and less than or equal to 21 years of age who is enrolled at a COG member institution is optional. PK sampling will not be sought for patients who are older than 21 years of age at the time of enrollment.

9.4 Evaluability for Disease Control and Response

Which Patients will be Considered Evaluable for RECIST Response:

Any eligible patient who receives at least one dose of CDX-011 will be considered evaluable for response with the following exception: if a patient receives non-protocol anti-cancer therapy during the response evaluation period after the patient is considered as having a partial or complete response but prior to confirmation of this status by tumor imaging and before progressive disease is noted, the individual will be considered inevaluable for the response endpoint. Further, patients who stop CDX-011 after the 1st evaluation because of toxicities or death will be considered evaluable for the response evaluation and will be counted as non-responders for the response endpoint.

Which Patients Will Be Considered Evaluable for Disease Control Success:

Any eligible patient who receives at least one dose of CDX-011 will be considered evaluable for response with the following exception: if a patient receives non-protocol anti-cancer therapy during the first four months of therapy or first six cycles of therapy, whichever occurs first, is considered as having a partial or complete response but prior to confirmation of this status by tumor imaging and before progressive disease is noted, the individual will be considered inevaluable for the disease control success endpoint.

Which Patients Will be Considered a Disease Control Success:

Any patient who is evaluated free of all detectable disease (complete response) or is considered as having a partial response or is considered as having stable disease (‘at least stable disease’) after four months of therapy or at the end of the sixth cycle, whichever occurs first.

Which Patients Will be Considered Not a Disease Control Success:

Any evaluable patient who does not meet the criteria for disease control success (complete response, partial response or stable disease) will be considered to not have experienced disease control success.

In particular, any patient who dies because of treatment-related toxicity during the first six cycles of therapy and within the first four months since starting treatment will be

considered not to have experienced disease control success. Also, any patient who is eligible, receives one dose of CDX-011 and is lost to follow-up at (for example) the end of cycle 2 will be considered not a disease control success (complete response, partial response or stable disease).

Patients who are not evaluable for both disease control and response evaluation may be replaced for the purposes of the statistical rule.

9.5 **Evaluability for Toxicity**

Tolerability of CDX-011 - An eligible patient will be considered for toxicity monitoring if one of the following occurs: (1) complete one cycle of CDX-011 prior to receiving non-protocol anticancer therapy; (2) die on protocol therapy for a reason considered possibly, probably or likely related to CDX-011; or (3) are removed from protocol therapy because of an adverse experience possibly, probably or likely related to CDX-011. A toxicity-evaluable patient will be considered in the analysis during the interval from study enrollment until the termination of protocol therapy. A toxicity-evaluable patient will be considered to have experienced an excessive toxicity event if: (1) the patient dies on protocol therapy for a reason considered possibly, probably or likely related to; or (2) experiences a dose-limiting toxicity (DLT). DLTs will be as defined in Section 5.1.1 of the protocol:

The analytic unit for monitoring for excessive toxicity will be the patient-cycle: Each cycle where the patient receives CDX-011 and does not receive non-protocol anticancer therapy will be considered in the analysis. If there is overwhelming evidence that the dose selected for this trial has a per-cycle-DLT probability of more than 30%, we will identify the regimen to the COG DSMC, Bone Tumor Committee leadership and CTEP as associated with a toxicity profile that may require modification of the regimen. We will use a Bayesian rule to monitor for excessive toxicity. We will assume a beta prior to distribution with α=0.6 and β=1.4. If this posterior probability of the chance of DLT is at least 30% exceeds 80%, we will identify the regimen to the COG DSMC, Bone Tumor leadership and CTEP as associated with a toxicity profile that may require modification of the regimen.

9.6 **Estimation of Disease Control and RECIST Response Rates**

P(R) and P(S) for each cohort defined by prior eribulin exposure will be estimated using the maximum likelihood estimates, *viz.,*

$$P(R) \hat{=} \hat{p}_R = \frac{Number\ of\ Patients\ Considered\ as\ PR\ or\ CR}{Number\ of\ Evaluable\ Patients\ in\ Cohort};$$

$$P(S) \hat{=} \hat{p}_S = \frac{Number\ of\ Patients\ With\ Disease\ Control\ at\ 4\ Months}{Number\ of\ Evaluable\ Patients\ in\ Cohort}$$

Confidence intervals will be constructed using the approximate normal distribution of each of the estimates and their asymptotic variances:

$$V\left(\hat{p}_R\right) \hat{=} \frac{\hat{p}_R\left(1-\hat{p}_R\right)}{Number\ of\ Evaluable\ Patients\ in\ Cohort};$$

$$V\left(\hat{p}_S\right) \hat{=} \frac{\hat{p}_S\left(1-\hat{p}_S\right)}{Number\ of\ Evaluable\ Patients\ in\ Cohort}$$

9.7 Statistical Considerations for Secondary Aim 1.2.3

9.7.1 *To determine the relationship of GPNMB expression by IHC to response in tumor specimens from patients:* Submission of archival tissue will be required for this study. The primary cohort to address this aim will be the patients who were not previously treated with eribulin. The GPNMB expression IHC result will be coded as an integer between 0 and 3 with 0 being no GPNMB expression and 3 indicating strong GPNMB expression. The outcome measure will be DC success (Yes *v.* No). Logistic regression using the categorical IHC result will be fitted to the data. The fitted coefficients from the logistic regression, and the p-value for the test of the hypothesis of no relationship between IHC result and probability of DC success will be used to characterize this secondary analysis. Trend will also be assessed using the actual IHC numerical value.

9.8 Gender and Minority Accrual Estimates

The gender and minority distribution of the study population is expected to be:

Racial Categories	**Ethnic Categories**				**Total**
	Not Hispanic or Latino		**Hispanic or Latino**		
	Female	**Male**	**Female**	**Male**	
American Indian/ Alaska Native	0	0	0	0	**0**
Asian	0	0	0	0	**0**
Native Hawaiian or Other Pacific Islander	0	0	0	0	**0**
Black or African American	2	6	0	0	**8**
White	9	17	1	3	**30**
More Than One Race	0	0	0	0	**0**
Total	**11**	**23**	**1**	**3**	**38**

This distribution was derived from ADVL0821, ADVL0921, ADVL1221.

10.0 EVALUATION CRITERIA

10.1 Common Terminology Criteria for Adverse Events (CTCAE)

This study will utilize version 4.0 of the CTCAE of the National Cancer Institute (NCI) for toxicity and performance reporting. A copy of the CTCAE version 4.0 can be downloaded from the CTEP website

(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm). Additionally, toxicities are to be reported on the appropriate case report forms.

Please note: 'CTCAE v4.0' is understood to represent the most current version of CTCAE v4.0 as referenced on the CTEP website (ie, v4.02 and all subsequent iterations prior to version 5.0).

10.2 Response Criteria for Patients with Solid Tumors

For the purposes of this study, patients should be evaluated for response following Cycles 2, 4 and 6 and following every 3rd cycle thereafter. Patients who have a RECIST response (CR or PR) at Cycle 6 will have confirmatory imaging after Cycle 8.

Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).[51] Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.

10.2.1 Disease Parameters

10.2.1.1 Measurable disease: Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm by chest x-ray, as ≥ 10 mm with CT scan, or ≥ 10 mm with calipers by clinical exam. All tumor measurements must be recorded in millimeters (or decimal fractions of centimeters).

10.2.1.2 Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph node must be ≥ 15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm). At baseline and in follow-up, only the short axis will be measured and followed.

10.2.1.3 Non-measurable disease: All other lesions (or sites of disease), including small lesions (longest diameter <10 mm or pathological lymph nodes with ≥ 10 to < 15 mm short axis), are considered non-measurable disease. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by CT or MRI), are considered as non-measurable.

Note: Cystic lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesions (neither measurable nor non-measurable) since they are, by definition, simple cysts.

'Cystic lesions' thought to represent cystic metastases can be considered as measurable lesions, if they meet the definition of measurability described above. However, if non-cystic lesions are present in the same patient, these are preferred for selection as target lesions.

10.2.1.4 Target lesions: All measurable lesions up to a maximum of 2 lesions per

organ and 5 lesions in total, representative of all involved organs, should be identified as **target lesions** and recorded and measured at baseline. Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, but in addition should be those that lend themselves to reproducible repeated measurements. It may be the case that, on occasion, the largest lesion does not lend itself to reproducible measurement in which circumstance the next largest lesion which can be measured reproducibly should be selected. A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be included in the sum, then only the short axis is added into the sum. The baseline sum diameters will be used as reference to further characterize any objective tumor regression in the measurable dimension of the disease.

10.2.1.5 Non-target lesions: All other lesions (or sites of disease) including any measurable lesions over and above the 5 target lesions should be identified as **non-target lesions** and should also be recorded at baseline. Measurements of these lesions are not required, but the presence, absence, or in rare cases unequivocal progression of each should be noted throughout follow-up.

10.2.2 Methods for Evaluation of Measurable Disease

All measurements should be taken and recorded in metric notation using a ruler or calipers. All baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 4 weeks before the beginning of the treatment.

The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be imaged but are assessable by clinical exam.

10.2.2.1 Clinical lesions: Clinical lesions will only be considered measurable when they are superficial (eg, skin nodules and palpable lymph nodes) and ≥ 10 mm diameter as assessed using calipers (eg, skin nodules). In the case of skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is recommended.

10.2.2.2 Chest x-ray: Lesions on chest x-ray are acceptable as measurable lesions when they are clearly defined and surrounded by aerated lung. However, CT is preferable.

10.2.2.3 Conventional CT and MRI: This guideline has defined measurability of lesions on CT scan based on the assumption that CT slice thickness is 5 mm or less. If CT scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness. MRI is also acceptable in certain situations (eg, for body scans).

Use of MRI remains a complex issue. MRI has excellent contrast, spatial, and temporal resolution; however, there are many image acquisition variables involved in MRI, which greatly impact image quality, lesion conspicuity, and measurement. Furthermore, the availability of MRI is variable globally. As with CT, if an MRI is performed, the technical specifications of the scanning sequences used should be optimized for the evaluation of the type and site of disease. Furthermore, as with CT, the modality used at follow-up should be the same as was used at baseline and the lesions should be measured/assessed on the same pulse sequence. It is beyond the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameters for all scanners, body parts, and diseases. Ideally, the same type of scanner should be used and the image acquisition protocol should be followed as closely as possible to prior scans. Body scans should be performed with breath-hold scanning techniques, if possible.

10.2.2.4 Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be used as a method of measurement. Ultrasound examinations cannot be reproduced in their entirety for independent review at a later date and, because they are operator dependent, it cannot be guaranteed that the same technique and measurements will be taken from one assessment to the next. If new lesions are identified by ultrasound in the course of the study, confirmation by CT or MRI is advised. If there is concern about radiation exposure at CT, MRI may be used instead of CT in selected instances.

10.2.2.5 Endoscopy, Laparoscopy: The utilization of these techniques for objective tumor evaluation is not advised. However, such techniques may be useful to confirm complete pathological response when biopsies are obtained or to determine relapse in trials where recurrence following complete response (CR) or surgical resection is an endpoint.

10.2.2.6 Cytology, Histology: These techniques can be used to differentiate between partial responses (PR) and complete responses (CR) in rare cases (eg, residual lesions in tumor types, such as germ cell tumors, where known residual benign tumors can remain).

The cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment when the measurable tumor has met criteria for response or stable disease is mandatory to differentiate between response or stable disease (an effusion may be a side effect of the treatment) and progressive disease.

10.2.3 Response Criteria

10.2.3.1 Evaluation of Target Lesions

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have

reduction in short axis to <10 mm.

Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

10.2.3.2 Evaluation of Non-Target Lesions

Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (<10 mm short axis).

Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits

Progressive Disease (PD): Appearance of one or more new lesions and/or *unequivocal progression* of existing non-target lesions. *Unequivocal progression* should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Although a clear progression of "non-target" lesions only is exceptional, the opinion of the treating physician should prevail in such circumstances, and the progression status should be confirmed at a later time by the review panel (or Principal Investigator).

10.2.3.3 Evaluation of Best Overall Response

The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.

For Patients with Measurable Disease (ie, Target Disease)

Target Lesions	Non-Target Lesions	New Lesions	Overall Response	Best Overall Response when Confirmation is Required*
CR	CR	No	CR	≥ 4 wks. Confirmation**
CR	Non-CR/Non-PD	No	PR	≥ 4 wks. Confirmation**
CR	Not evaluated	No	PR	
PR	Non-CR/Non-PD/not evaluated	No	PR	
SD	Non-CR/Non-PD/not evaluated	No	SD	documented at least once ≥ 4 wks. from baseline**
PD	Any	Yes or No	PD	no prior SD, PR or CR
Any	PD***	Yes or No	PD	
Any	Any	Yes	PD	

*See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.
**Only for non-randomized trials with response as primary endpoint.
***In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as disease progression.

Note: Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as "*symptomatic deterioration.*" Every effort should be made to document the objective progression even after discontinuation of treatment.

For Patients with Non-Measurable Disease (ie, Non-Target Disease)

Non-Target Lesions	New Lesions	Overall Response
CR	No	CR
Non-CR/non-PD	No	Non-CR/non-PD*
Not all evaluated	No	not evaluated
Unequivocal PD	Yes or No	PD
Any	Yes	PD

* 'Non-CR/non-PD' is preferred over 'stable disease' for non-target disease since SD is increasingly used as an endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is not advised

10.2.4 Duration of Response

10.2.4.1 Duration of overall response: The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).

The duration of overall CR is measured from the time measurement criteria are first met for CR until the first date that progressive disease is objectively documented.

10.2.4.2 Duration of stable disease: Stable disease is measured from the start of the treatment until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, including the baseline measurements.

11.0 ADVERSE EVENT REPORTING REQUIREMENTS

11.1 Purpose

Adverse event (AE) data collection and reporting, which are required as part of every clinical trial, are done to ensure the safety of patients enrolled in the studies as well as those who will enroll in future studies using similar agents. Certain adverse events must be reported in an expedited manner to allow for timelier monitoring of patient safety and care. The following sections provide information about expedited reporting.

11.2 Expedited Reporting Requirements – Serious Adverse Events (SAEs)

To ensure compliance with these regulations/this guidance, as IND/IDE sponsor, NCI requires that AEs be submitted according to the timeframes in the AE reporting table assigned to the protocol, using the CTEP Adverse Event Reporting System (CTEP-AERS).

Any AE that is serious qualifies for expedited reporting. An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A Serious Adverse Event (SAE) is any adverse drug event (experience) occurring at any dose that results in ANY of the following outcomes:

1) Death.
2) A life-threatening adverse drug experience.
3) An adverse event resulting in inpatient hospitalization or prolongation of existing hospitalization (for ≥ 24 hours). This does not include hospitalizations that are part of routine medical practice.
4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions.
5) A congenital anomaly/birth defect.
6) Important Medical Events (IME) that may not result in death, be life threatening, or require hospitalization may be considered a serious adverse drug experience when, based upon medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.

11.3 Specific Examples for Expedited Reporting

11.3.1 SAEs Occurring More than 30 Days After Last Dose of Study Drug

Any Serious Adverse Event that occurs more than 30 days after the last administration of the investigational agent/intervention **and** has an attribution of a possible, probable, or definite relationship to the study therapy must be reported according to the CTEP-AERS reporting table in this protocol.

11.3.2 Persistent or Significant Disabilities/Incapacities

Any AE that results in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions (formerly referred to as disabilities), congenital anomalies or birth defects, must be reported via CTEP-AERS if it

occurs at any time following treatment with an agent under a NCI IND/IDE since these are considered serious AEs.

11.3.3 Death

Reportable Categories of Death

- Death attributable to a CTCAE term.
- Death Neonatal: A disorder characterized by cessation of life during the first 28 days of life.
- Sudden Death NOS: A sudden (defined as instant or within one hour of the onset of symptoms) or an unobserved cessation of life that cannot be attributed to a CTCAE term associated with Grade 5.
- Death NOS: A cessation of life that cannot be attributed to a CTCAE term associated with Grade 5.
- Death due to progressive disease should be reported as ***Grade 5 "Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other (Progressive Disease)"*** under the system organ class (SOC) of the same name. Evidence that the death was a manifestation of underlying disease (*e.g.*, radiological changes suggesting tumor growth or progression: clinical deterioration associated with a disease process) should be submitted.

Any death occurring ***within 30 days*** of the last dose, regardless of attribution to the investigational agent/intervention requires expedited reporting within 24 hours.

Any death occurring ***greater than 30 days*** after the last dose of the investigational agent/intervention requires expedited reporting within 24 hours **only if** it is possibly, probably, or definitely related to the investigational agent/intervention.

11.3.4 Secondary Malignancy

A ***secondary malignancy*** is a cancer caused by treatment for a previous malignancy (eg, treatment with investigational agent/intervention, radiation or chemotherapy). A metastasis of the initial neoplasm is not considered a secondary malignancy.

The NCI requires all secondary malignancies that occur following treatment with an agent under an NCI IND/IDE be reported via CTEP-AERS. Three options are available to describe the event:

- Leukemia secondary to oncology chemotherapy
- Myelodysplastic syndrome
- Treatment related secondary malignancy

Any malignancy possibly related to cancer treatment (including AML/MDS) must also be reported via the routine reporting mechanisms outlined in this protocol.

11.3.5 Second Malignancy

A second malignancy is one unrelated to the treatment of a prior malignancy (and is **NOT** a metastasis from the initial malignancy). Second malignancies require **ONLY** routine reporting via CDUS unless otherwise specified.

11.3.6 Pregnancy, Fetal Death, and Death Neonatal

NOTE: When submitting CTEP-AERS reports for "Pregnancy", "Pregnancy loss", or "Neonatal loss", the Pregnancy Information Form, available at:

http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/PregnancyReportForm.pdf, needs to be completed and faxed along with any additional medical information to 301-230-0159. The potential risk of exposure of the fetus to the investigational agent(s) or chemotherapy agent(s) should be documented in the "Description of Event" section of the CTEP-AERS report.

11.3.6.1 Pregnancy

Patients who become pregnant on study risk intrauterine exposure of the fetus to agents that may be teratogenic. For this reason, pregnancy needs to be reported in an expedited manner via CTEP-AERS as **Grade 3 "*Pregnancy, puerperium and perinatal conditions - Other (pregnancy)*"** under the ***Pregnancy, puerperium and perinatal conditions*** SOC.

Pregnancy needs to be followed **until the outcome is known**. If the baby is born with a birth defect or anomaly, then a second CTEP-AERS report is required.

11.3.6.2 Fetal Death

Fetal death, defined in CTCAE as "*A disorder characterized by death in utero; failure of the product of conception to show evidence of respiration, heartbeat, or definite movement of a voluntary muscle after expulsion from the uterus, without possibility of resuscitation*", needs to be reported expeditiously, as **Grade 4 "*Pregnancy, puerperium and perinatal conditions - Other (pregnancy loss)*"**. Do NOT report a fetal death as a Grade 5 event since CTEP-AERS recognizes any Grade 5 event as a patient death.

11.3.6.3 Death Neonatal

Neonatal death, defined in CTCAE as *"A disorder characterized by cessation of life occurring during the first 28 days of life*" needs to be reported expeditiously, as **Grade 4 "*General disorders and administration - Other (neonatal loss)*" when the death is the result of a patient pregnancy or pregnancy in partners of men on study**. Do NOT report a neonatal death resulting from a patient pregnancy or pregnancy in partners of men on study as a Grade 5 event since CTEP-AERS recognizes any Grade 5 event as a patient death.

11.4 Reporting Requirements for Specialized AEs

11.4.1 Baseline AEs

Although a pertinent positive finding identified on baseline assessment is not an AE, when possible it is to be documented as "Course Zero" using CTCAE terminology and grade. An expedited AE report is not required if a patient is entered on a protocol with a pre-existing condition (eg, elevated laboratory value, diarrhea). The baseline AE must be re-assessed throughout the study and reported if it fulfills expedited AE reporting guidelines.

a. If the pre-existing condition worsens in severity, the investigator must reassess the event to determine if an expedited report is required.
b. If the AE resolves and then recurs, the investigator must re-assess the event to determine if an expedited report is required.

c. No modification in grading is to be made to account for abnormalities existing at baseline.

11.4.2 Persistent AEs

A persistent AE is one that extends continuously, without resolution between treatment cycles/courses.

ROUTINE reporting: The AE must be reported only once unless the grade becomes more severe in a subsequent course. If the grade becomes more severe the AE must be reported again with the new grade.

EXPEDITED reporting: The AE must be reported only once unless the grade becomes more severe in the same or a subsequent course.

11.4.3 Recurrent AEs

A recurrent AE is one that occurs and resolves during a cycle/course of therapy and then reoccurs in a later cycle/course.

ROUTINE reporting: An AE that resolves and then recurs during a subsequent cycle/course must be reported by the routine procedures.

EXPEDITED reporting: An AE that resolves and then recurs during a subsequent cycle/course does not require CTEP-AERS reporting unless:

1) The grade increases OR
2) Hospitalization is associated with the recurring AE.

11.5 Exceptions to Expedited Reporting

11.5.1 Specific Protocol Exceptions to Expedited Reporting (SPEER)

SPEER: Is a subset of AEs within the Comprehensive Adverse Events and Potential Risks (CAEPR) that contains a list of events that are considered expected for CTEP-AERS reporting purposes. (Formerly referred to as the Agent Specific Adverse Event List (ASAEL).)

AEs listed on the SPEER should be reported expeditiously by investigators to the NCI via CTEP-AERS ONLY if they exceed the grade of the event listed in parentheses after the event. If the CAEPR is part of a combination IND using multiple investigational agents and has an SAE listed on different SPEERs, use the lower of the grades to determine if expedited reporting is required.

11.5.2 Special Situations as Exceptions to Expedited Reporting

An expedited report may not be required for a specific protocol where an AE is listed as expected. The exception or acceptable reporting procedures will be specified in the protocol. The protocol specific guidelines supersede the NCI Adverse Event Reporting Guidelines. These special situations are listed under the CTEP-AERS reporting table for this protocol.

11.6 Reporting Requirements - Investigator Responsibility

Clinical investigators in the treating institutions and ultimately the Study Chair have the primary responsibility for AE identification, documentation, grading, and assignment of attribution to the investigational agent/intervention. It is the responsibility of the treating physician to supply the medical documentation needed to support the expedited AE reports in a timely manner.

Note: All expedited AEs (reported via CTEP-AERS) must also be reported via routine reporting. Routine reporting is accomplished via the Adverse Event (AE) Case Report Form (CRF) within the study database.

11.7 General Instructions for Expedited Reporting via CTEP-AERS

The descriptions and grading scales found in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting and are located on the CTEP website at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. All appropriate treatment areas should have access to a copy of the CTCAE.

An expedited AE report for all studies utilizing agents under an NCI IND/IDE must be submitted electronically to NCI via CTEP-AERS at: https://eapps-ctep.nci.nih.gov/ctepaers

In the rare situation where Internet connectivity is disrupted, the 24-hour notification is to be made to the NCI for agents supplied under a CTEP IND by telephone call to 301-897-7497.
In addition, once Internet connectivity is restored, a 24-hour notification that was phoned in must be entered into the electronic CTEP-AERS system by the original submitter of the report at the site.

- Expedited AE reporting timelines are defined as:
  - **24-Hour; 5 Calendar Days -** The AE must initially be reported via CTEP-AERS within 24 hours of learning of the event, followed by a complete expedited report within 5 calendar days of the initial 24-hour report.
  - **7 Calendar Days -** A complete expedited report on the AE must be submitted within 7 calendar days of the investigator learning of the event.

- Any event that results in a persistent or significant incapacity/substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect, or is an IME, which based upon the medical judgment of the investigator may jeopardize the patient and require intervention to prevent a serious AE, must be reported via CTEP-AERS **if the event occurs following investigational agent administration.**

- Any death occurring within 30 days of the last dose, regardless of attribution to an agent/intervention under an NCI IND/IDE requires expedited reporting **within 24 hours**.
- Any death occurring greater than 30 days of the last dose with an attribution of possible, probable, or definite to an agent/intervention under an NCI IND/IDE requires expedited reporting **within 24 hours**.

CTEP-AERS Medical Reporting includes the following requirements as part of the report: 1) whether the patient has received at least one dose of an investigational agent on this study; 2) the characteristics of the adverse event including the *grade* (severity), the *relationship to the study therapy* (attribution), and the *prior experience* (expectedness) of the adverse event; 3) the Phase (1, 2, or 3) of the trial; and 4) whether or not hospitalization or prolongation of hospitalization was associated with the event.

Any medical documentation supporting an expedited report (eg, H & P, admission and/or notes, consultations, ECG results, etc.) MUST be faxed within 48-72 hours to the NCI. NOTE: English is required for supporting documentation submitted to the numbers listed below in order for the NCI to meet the regulatory reporting timelines.

Fax supporting documentation **for AEs related to investigational agents supplied under a CTEP IND** to: **301-230-0159** (back-up: 301-897-7404).

Also: Fax or email supporting documentation to COG for **all** IND studies (Fax# 310-640-9193; email: COGAERS@childrensoncologygroup.org; Attention: COG AERS Coordinator).

- **ALWAYS include the ticket number on all faxed documents.**
- **Use the NCI protocol number and the protocol-specific patient ID provided during trial registration on all reports.**

11.8 **Reporting Table for Late Phase 2 and Phase 3 Studies**

Expedited Reporting Requirements for Adverse Events that Occur on Studies under an IND/IDE within 30 Days of the Last Administration of the Investigational Agent/Intervention [1]

FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)
NOTE: Investigators **MUST** immediately report to the sponsor (NCI) **ANY** Serious Adverse Events, whether or not they are considered related to the investigational agent(s)/intervention (21 CFR 312.64)
An adverse event is considered serious if it results in **ANY** of the following outcomes:
1) Death.
2) A life-threatening adverse event.
3) Any AE that results in inpatient hospitalization or prolongation of existing hospitalization for ≥ 24 hours. This does not include hospitalizations that are part of routine medical practice.
4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions.
5) A congenital anomaly/birth defect.
6) Important Medical Events (IME) that may not result in death, be life threatening, or require hospitalization may be considered serious when, based upon medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6.)

ALL SERIOUS adverse events that meet the above criteria **MUST** be immediately reported to the NCI via CTEP-AERS within the timeframes detailed in the table below.

<table>
<tr><th>Hospitalization</th><th>Grade 1 Timeframes</th><th>Grade 2 Timeframes</th><th>Grade 3 Timeframes</th><th>Grade 4 & 5 Timeframes</th></tr>
<tr><td>Resulting in Hospitalization ≥ 24 hrs</td><td colspan="3">7 Calendar Days</td><td rowspan="2">24-Hour Notification 5 Calendar Days</td></tr>
<tr><td>Not resulting in Hospitalization ≥ 24 hrs</td><td colspan="2">Not Required</td><td>7 Calendar Days</td></tr>
</table>

NOTE: Protocol specific exceptions to expedited reporting of serious adverse events are found in the Specific Protocol Exceptions to Expedited Reporting (SPEER) portion of the CAEPR. Additional Special Situations as Exceptions to Expedited Reporting are listed below.

Expedited AE reporting timelines are defined as:
"24-Hour; 5 Calendar Days" - The AE must initially be reported via CTEP-AERS within 24 hours of learning of the AE, followed by a complete expedited report within 5 calendar days of the initial 24-hour notification.
"7 Calendar Days" - A complete expedited report on the AE must be submitted within 7 calendar days of learning of the AE.

[1]SAEs that occur more than 30 days after the last administration of investigational agent/intervention and have an attribution of possible, probable, or definite require reporting as follows:
Expedited 24-hour notification followed by complete report within 5 calendar days for:
- All Grade 4, and Grade 5 AEs

Expedited 7 calendar day reports for:
- Grade 2 adverse events resulting in hospitalization or prolongation of hospitalization
- Grade 3 adverse events

11.9 **Protocol Specific Additional Instructions and Reporting Exceptions**

- **Grades 1- 4 myelosuppression (anemia, neutropenia, thrombocytopenia) do not require expedited reporting.**
- **Grades 1-2 peripheral neuropathy do not require expedited reporting.**

11.10 **Routine Reporting of Adverse Events**

Note: The guidelines below are for routine reporting of study specific adverse events on the COG case report forms and do not affect the requirements for CTEP-AERS reporting.

Routine reporting is accomplished via the Adverse Event (AE) Case Report Form (CRF) within the study database. For this study, routine reporting will include all CTEP-AERS reportable events and Grade 3 and higher non-hematologic and Grade 4 and higher hematologic Adverse Events

12.0 STUDY REPORTING AND MONITORING

The Case Report Forms and the submission schedule are posted on the COG web site with each protocol under "*Data Collection/Specimens*". A submission schedule is included.

12.1 **CDUS**

This study will be monitored by the Clinical Data Update System (CDUS). Cumulative CDUS data will be submitted quarterly to CTEP by electronic means. Reports are due January 31, April 30, July 31 and October 31. This is not a responsibility of institutions participating in this trial.

12.2 **Data and Safety Monitoring Committee**

To protect the interests of patients and the scientific integrity for all clinical trial research by the Children's Oncology Group, the COG Data and Safety Monitoring Committee (DSMC) reviews reports of interim analyses of study toxicity and outcomes prepared by the study statistician, in conjunction with the study chair's report. The DSMC may recommend the study be modified or terminated based on these analyses.

Toxicity monitoring is also the responsibility of the study committee and any unexpected frequency of serious events on the trial are to be brought to the attention of the DSMC. The study statistician is responsible for the monitoring of the interim results and is expected to request DSMC review of any protocol issues s/he feels require special review. Any COG member may bring specific study concerns to the attention of the DSMC.

The DSMC approves major study modifications proposed by the study committee prior to implementation (eg, termination, dropping an arm based on toxicity results or other trials reported, increasing target sample size, etc.). The DSMC determines whether and to whom outcome results may be released prior to the release of study results at the time specified in the protocol document.

12.3 **CRADA/CTA**

NCI/DCTD Standard Language to Be Incorporated into All Protocols Involving Agent(s) Covered by a Clinical Trials Agreement (CTA), a Cooperative Research and Development Agreement (CRADA) or a Clinical Supply Agreement, hereinafter referred to as Collaborative Agreement:

The agent(s) supplied by CTEP, DCTD, NCI used in this protocol is/are provided to the NCI under a Collaborative Agreement (CRADA, CTA, CSA) between the Pharmaceutical Company(ies) (hereinafter referred to as "Collaborator(s)") and the NCI Division of Cancer Treatment and Diagnosis. Therefore, the following obligations/guidelines, in addition to the provisions in the "Intellectual Property Option to Collaborator" (http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm) contained within the terms of award, apply to the use of the Agent(s) in this study:

1. Agent(s) may not be used for any purpose outside the scope of this protocol, nor can Agent(s) be transferred or licensed to any party not participating in the clinical study. Collaborator(s) data for Agent(s) are confidential and proprietary to Collaborator(s) and shall be maintained as such by the investigators. The protocol documents for studies utilizing Agents contain confidential information and should not be shared or distributed without the permission of the NCI. If a copy of this protocol is requested by a patient or patient's family member participating on the study, the individual should sign a confidentiality agreement. A suitable model agreement can be downloaded from: http://ctep.cancer.gov.

2. For a clinical protocol where there is an investigational Agent used in combination with (an)other Agent(s), each the subject of different Collaborative Agreements, the access to and use of data by each Collaborator shall be as follows (data pertaining to such combination use shall hereinafter be referred to as "Multi-Party Data"):

    a. NCI will provide all Collaborators with prior written notice regarding the existence and nature of any agreements governing their collaboration with NCI, the design of the proposed combination protocol, and the existence of any obligations that would tend to restrict NCI's participation in the proposed combination protocol.

    b. Each Collaborator shall agree to permit use of the Multi-Party Data from the clinical trial by any other Collaborator solely to the extent necessary to allow said other Collaborator to develop, obtain regulatory approval or commercialize its own Agent.

    c. Any Collaborator having the right to use the Multi-Party Data from these trials must agree in writing prior to the commencement of the trials that it will use the Multi-Party Data solely for development, regulatory approval, and commercialization of its own Agent.

3. Clinical Trial Data and Results and Raw Data developed under a Collaborative Agreement will be made available to Collaborator(s), the NCI, and the FDA, as appropriate and unless additional disclosure is required by law or court order as described in the IP Option to Collaborator (http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm).
   Additionally, all Clinical Data and Results and Raw Data will be collected, used and disclosed consistent with all applicable federal statutes and regulations for the protection of human subjects, including, if applicable, the *Standards for Privacy of Individually Identifiable Health Information* set forth in 45 C.F.R. Part 164.

4. When a Collaborator wishes to initiate a data request, the request should first be sent to the NCI, who will then notify the appropriate investigators (Group Chair for Cooperative Group studies, or PI for other studies) of Collaborator's wish to contact them.

5. Any data provided to Collaborator(s) for Phase 3 studies must be in accordance with the guidelines and policies of the responsible Data Monitoring Committee (DMC), if there is a DMC for this clinical trial.

6. Any manuscripts reporting the results of this clinical trial must be provided to CTEP by the Group office for Cooperative Group studies or by the principal investigator for non-Cooperative Group studies for immediate delivery to Collaborator(s) for advisory review and comment prior to submission for publication. Collaborator(s) will have 30 days from the date of receipt for review. Collaborator shall have the right to request that publication be delayed for up to an additional 30 days in order to ensure that Collaborator's confidential and proprietary data, in addition to Collaborator(s)'s intellectual property rights, are protected. Copies of abstracts must be provided to CTEP for forwarding to Collaborator(s) for courtesy review as soon as possible and preferably at least three (3) days prior to submission, but in any case, prior to presentation at the meeting or publication in the proceedings. Press releases and other media presentations must also be forwarded to CTEP prior to release. Copies of any manuscript, abstract and/or press release/media presentation should be sent to:

   Email: ncicteppubs@mail.nih.gov

   The Regulatory Affairs Branch will then distribute them to Collaborator(s). No publication, manuscript or other form of public disclosure shall contain any of Collaborator's confidential/ proprietary information.

13.0 SURGICAL GUIDELINES

See COG Surgical Guidelines for osteosarcoma at:
https://members.childrensoncologygroup.org/_files/Disc/surgery/handbooks/OsteoBoneHandbook.pdf

14.0 PATHOLOGY GUIDELINES AND SPECIMEN REQUIREMENTS

All patients enrolling on this protocol require institutional histological confirmation of osteosarcoma at the time of original diagnosis or relapse. Patients are required to submit archival tumor samples (collected at original diagnosis or at relapse or at any subsequent resections or biopsies) for immunohistochemical analysis.

Please note: At enrollment, all patients must have adequate tumor specimen available for submission as detailed in Section 3.2.3.

Autopsy
In the event of patient death on AOST1521, a complete unrestricted postmortem examination is strongly encouraged. For patients enrolled on AOST06B1at COG sites, tissue submission at autopsy is requested. (See AOST06B1 protocol.)

15.0 SPECIAL STUDIES SPECIMEN REQUIREMENTS

15.1 Tumor GPNMB Expression (mandatory participation)

15.1.1 [redacted]

[redacted]

15.2 **Pharmacokinetics**

Participation in the PK studies is limited to COG member institutions. Serial blood samples for the assessment of CDX-011, CR011 antibody and MMAE are **required** for the first 6 evaluable patients ≤ 14 years of age enrolled at a COG member site. Serial blood samples for the assessment of CDX-011, CR011 antibody and MMAE are **optional** for patients > 14 years of age and ≤ 21 years of age enrolled at a COG member site.

15.2.1 Timing of pharmacokinetic sampling

Blood samples will be obtained in Cycle 1 on Days 1, 4 (+/- 1 day), 7 and 21 at the following 10 time points related to CDX-011 dosing:

- Time 0 (pre-dose)
- End of infusion
- 1 hour post infusion
- 2 hours post infusion
- 4 hours post infusion
- 8 hours post infusion
- 24 hours (+/- 4 hours) post infusion
- 4 days (+/- 1 day) post infusion
- 7 days post infusion
- 21 days post infusion

15.2.2 Sample Collection and Processing

[redacted]

15.2.3 Sample Labeling and Shipping

[redacted]

[redacted]

16.0 IMAGING STUDIES REQUIRED AND GUIDELINES FOR OBTAINING

Timing of protocol therapy administration, response assessment studies, and surgical interventions are based on schedules derived from the experimental design or on established standards of care. Minor unavoidable departures (up to 72 hours) from protocol directed therapy and/or disease evaluations (and up to 1 week for surgery) for valid clinical, patient and family logistical, or facility, procedure and/or anesthesia scheduling issues are acceptable (except where explicitly prohibited within the protocol).

16.1 Required and Recommended Osteosarcoma Imaging

Site	Anatomic Imaging	Functional Imaging	Timing
Primary tumor and bone metastases	AP and lateral radiographs		At presentation, following Cycles 2, 4, 6, and following every third cycle thereafter.
Primary tumor and bone metastases	CT or MRI with gadolinium		At presentation, following Cycles 2, 4, 6*, and following every third cycle thereafter.
Chest	CT		At presentation, following Cycles 2, 4, 6, and following every third cycle thereafter.
Whole body		^{18}FDG PET **or** MDP bone scintigraphy (recommended, not required)	Recommended at presentation. If a bone scan or ^{18}FDG PET is positive, it should be repeated following Cycles 2, 4, 6 and following every third cycle thereafter.

*For patients who undergo a surgical resection following Cycle 6, either a CT scan or MRI post-surgery to establish a new baseline is strongly recommended before re-initiating CDX-011 therapy.

NOTE: patients who have a RECIST response (CR or PR) at Cycle 6 will have confirmatory imaging after Cycle 8.

16.2 Technical Guidelines for Imaging Studies

16.2.1 CT and MRI guidelines are available on the COG Member site at: http://members.childrensoncologygroup.org/_files/reference/RefMaterial/DiagnosticImagingGuidelines_MRI&CT.pdf

16.2.2 X-ray

AP and lateral radiographs of primary tumor and bone metastases

16.2.3 Bone Scan (Recommended)

MDP bone scintigraphy

- Whole body bone scintigraphy should be performed and include planar images of the skeleton, including anterior and posterior views of the axial skeleton. Anterior and/or posterior views should be obtained of the appendicular skeleton.
- Delayed (skeletal phase) images should be performed in all cases with flow and blood pool images as per local custom and clinical need.
- Dose Administration: Dose administered should be according to standard weight-based protocols. Injection site should be away from lesion extremity or contralateral extremity if flow imaging is to be performed. Three-phase imaging is not required unless warranted by symptoms for a focal lesion to assess hyperemia.
- Imaging Parameters: Whole body delayed imaging is acquired 2-3 hours after injection of the radiopharmaceutical. Spot views should be acquired of specific sites of symptoms or of any sites of abnormality as warranted by the whole body views.
- Single-photon emission computed tomography (SPECT) is recommended, but not required, particularly in cases with suspicion of lung metastases.
- SPECT Imaging: SPECT should be performed of the lesion site. SPECT imaging should be performed as recommended by the camera manufacturer. Typical acquisition and processing parameters are 360° circular orbit, 60–120 stops, 64 ´ 64 ´ 16 or greater matrix, and 10–40 s/stop. An equivalent total number of counts should be acquired if continuous acquisition is used.
- Special Consideration: Imaging of pelvis can be difficult due to overlying bladder activity. To lessen this problem, repeat imaging can be performed immediately after patient voiding. Bladder catheterization may be used, but should be reserved for patients in whom visualization of the pelvis is essential. For SPECT acquisition of the pelvis: Single or multiple rapid (5-10 min/acquisition) SPECT acquisition(s) are preferred to avoid artifacts caused by changing activity in the bladder. Bladder artifacts are exaggerated in the plane in which the SPECT acquisition begins and ends. Beginning SPECT acquisition with the camera heads in the left and right lateral positions (for dual-head camera) or posterior position (for single-head camera) will help reduce bladder filling artifact.

16.2.4 [^{18}F]–Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Imaging (Recommended)

FDG PET imaging is optional, but is encouraged for all patients. The primary lesion must be ≥ 1 cm on baseline anatomic imaging in order for a FDG PET scan to be performed. If done, FDG PET imaging should be performed prior to the start of therapy and following Cycle 2, Cycle 4, Cycle 6 and following every 3rd cycle thereafter.

Patient Guidelines

The patient should fast for at least 4 hours prior to injection of FDG. FDG PET imaging may follow a MUGA study on the same day, or FDG PET imaging may be performed on the day preceding this study. Plasma glucose should be checked and, if the patient is hyperglycemic (plasma glucose > 250 mg/dL), appropriate treatment with small doses of insulin may be given to bring the plasma glucose into the normal range prior to FDG PET imaging. However, insulin administration may result in excessive muscle uptake of FDG and consequent tumor non-visualization. If possible, the study should be postponed until the plasma glucose is under better control.

Good hydration is required, as the primary route of FDG excretion is renal. The patient should drink water or receive intravenous fluids (not containing dextrose) after FDG injection to promote urinary excretion of the radioactive substrate. After injection, the patient must be kept in a resting state for 45-60 minutes prior to imaging. The patient should empty the bladder immediately prior to imaging.

Imaging Technique

The technique will vary by local institutional guidelines. In general, FDG is administered intravenously at a dose of 0.125-0.200 mCi/kg or by algorithms that adjust the dose by body surface area, with a minimum total dose of 2.0 mCi and maximum total dose of 20.0 mCi.

The body should be imaged from the top of the ears to the bottom of the feet. If there is suspicion of involvement of the skull or skull contents, the volume that is imaged should be expanded.

Imaging with a dedicated positron emission tomograph/computed tomography (PET/CT) camera is standard.

The length of time needed to perform head to toe CT will depend on the patient's height but will be approximately 45 seconds. Contiguous axial images should be obtained at 5 mm thickness using 90 mA and 120 Kv and adjusted for local institutional protocol. No oral or IV contrast is required but either or both are permissible and may be of benefit in cases where intraabdominal or pelvic pathology is a specific concern. With regard to patient positioning, the arms can be placed in a comfortable position at the patient's sides as long as they fit into the field of view. If the patient is large it may be necessary to lay the arms across the abdomen and hold in position with a stabilizing device.

Study Processing

The FDG PET study is processed for display by an iterative reconstruction algorithm. FDG activity should be corrected for attenuation, scatter, and radioactive decay. Attenuation correction is necessary, as apparent uptake will otherwise vary with depth of the lesion in the body and the nature of surrounding tissues. The procedure used for attenuation correction should be recorded. The level of tumor uptake is assessed subjectively by visual inspection and semi-quantitatively by determination of standardized uptake values (SUV). Uptake time, glucose levels, and partial volume effects influence both methods. The SUV

method is also dependent on body weight, and correction of SUV by normalizing for body surface area (BSA) reduces this dependency on body weight. SUVs should be calculated for lesions known to be 1.2 cm or larger in diameter. Smaller lesions may have underestimated SUVs due to partial volume averaging effects at typical scanner resolutions (0.6-1.2 cm).

To calculate the SUV, a region of interest (ROI) should be carefully drawn around as much of the area of elevated FDG uptake as can be done. The SUV should be calculated as SUV_{BSA} = ROI activity concentration (nCi/cc) x BSA / injected activity (nCi). SUV_{MAX} is obtained by determining the activity of the pixel with the highest FDG uptake.

The BSA is calculated from body mass (kg) and height (cm) using an appropriate algorithm. The SUV_{BSA} for each measured lesion should be recorded and the technique for assessing SUV_{BSA} should be consistent on follow-up studies.

RELATIONSHIP BETWEEN CHANGE IN SINGLE DIAMETER (RECIST), PRODUCT OF TWO DIAMETERS (WHO), AND THREE PERPENDICULAR DIAMETERS ("VOLUME")

	Diameter, 2R	Product, $(2R)^2$	Volume, $4/3\pi R^3$
Response	**Decrease**	**Decrease**	**Decrease**
	30%	50%	65%
	50%	75%	87%
Disease Progression	**Increase**	**Increase**	**Increase**
	12%	25%	40%
	20%	44%	73%
	25%	56%	95%
	30%	69%	120%



COG GUIDELINE: TUMOR SIZE MEASUREMENT BASED ON CROSS-SECTIONAL IMAGING

A, B, C, D, & E are contiguous parallel slices in the X-Y plane (usually axial) showing the tumor

W and T are the maximal perpendicular diameters on the slice (C in this example) showing the largest surface area

Tumor length in the Z-axis (L) (perpendicular to X-Y plane) can be obtained either by the [a] (difference in table position of the first and last slices showing the tumor *plus* one *slice* thickness), or [b] the product of ([slice thickness + gap] and the number of slices showing the tumor) *minus* one *gap* distance

- WHO criteria: TxW is used
- RECIST: the larger of the two (T & W) is used (W in this example)
- Elliptical model volume=0.5 LxWxT
- The same modality and measurement method used in the initial imaging should be used in follow ups

Target lesions at baseline must measure greater than 1 cm; if these target lesions decrease in size to below 1 cm, care should be taken in measuring and inadvertently progressing a patient due to minimal changes in measurement from a nadir value below 1 cm, which may be within measurement error. When multiple primary or metastatic masses are present, all masses will be described. However, up to 5 target masses should be measured, using the same method in subsequent follow ups.

APPENDIX I: CTEP AND CTSU REGISTRATION PROCEDURES

CTEP INVESTIGATOR REGISTRATION PROCEDURES

Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) policy require all investigators participating in any NCI-sponsored clinical trial to register and to renew their registration annually.

Registration requires the submission of:

- a completed ***Statement of Investigator Form*** (FDA Form 1572) with an original signature
- a current Curriculum Vitae (CV)
- a completed and signed ***Supplemental Investigator Data Form*** (IDF)
- a completed ***Financial Disclosure Form*** (FDF) with an original signature

Fillable PDF forms and additional information can be found on the CTEP website at <http://ctep.cancer.gov/investigatorResources/investigator_registration.htm>. For questions, please contact the ***CTEP Investigator Registration Help Desk*** by email at <pmbregpend@ctep.nci.nih.gov>.

CTEP Associate Registration Procedures / CTEP-IAM Account

The Cancer Therapy Evaluation Program (CTEP) Identity and Access Management (IAM) application is a web-based application intended for use by both Investigators (i.e., all physicians involved in the conduct of NCI-sponsored clinical trials) and Associates (i.e., all staff involved in the conduct of NCI-sponsored clinical trials).

Associates will use the CTEP-IAM application to register (both initial registration and annual re-registration) with CTEP and to obtain a user account.

Investigators will use the CTEP-IAM application to obtain a user account only. (See CTEP Investigator Registration Procedures above for information on registering with CTEP as an Investigator, which must be completed before a CTEP-IAM account can be requested.)

An active CTEP-IAM user account will be needed to access all CTEP and CTSU (Cancer Trials Support Unit) websites and applications, including the CTSU members' website.

Additional information can be found on the CTEP website at <http://ctep.cancer.gov/branches/pmb/associate_registration.htm>. For questions, please contact the ***CTEP Associate Registration Help Desk*** by email at <ctepreghelp@ctep.nci.nih.gov>.

CTSU REGISTRATION PROCEDURES

This study is supported by the NCI Cancer Trials Support Unit (CTSU).

Downloading Site Registration Documents:

Site registration forms may be downloaded from the AOST1521 protocol page located on the CTSU members' website. Permission to view and download this protocol and its supporting documents is restricted and is based on person and site roster assignment housed in the CTSU RSS.

- Go to https://www.ctsu.org and log in to the members' area using your CTEP-IAM username and password
- Click on the Protocols tab in the upper left of your screen
- Click on the COG link to expand, then select trial protocol AOST1521
- Click on the Site Registration Documents link

Requirements for AOST1521 Site Registration:

- CTSU IRB Certification (for sites not participating via the CIRB)
- CTSU IRB/Regulatory Approval Transmittal Sheet (for sites not participating via the NCI CIRB)

Submitting Regulatory Documents:

Submit completed forms along with a copy of your IRB Approval to the CTSU Regulatory Office, where they will be entered and tracked in the CTSU RSS.

CTSU Regulatory Office
1818 Market Street, Suite 1100
Philadelphia, PA 19103
Phone: 1-866-651-2878
Fax: 215-569-0206
E-mail: CTSURegulatory@ctsu.coccg.org (for regulatory document submission only)

Checking Your Site's Registration Status:

Check the status of your site's registration packets by querying the RSS site registration status page of the members' section of the CTSU website. (Note: Sites will not receive formal notification of regulatory approval from the CTSU Regulatory Office.)

- Go to https://www.ctsu.org and log in to the members' area using your CTEP-IAM username and password
- Click on the Regulatory tab at the top of your screen
- Click on the Site Registration tab
- Enter your 5-character CTEP Institution Code and click on Go

APPENDIX II: YOUTH INFORMATION SHEETS

INFORMATION SHEET REGARDING RESEARCH STUDY AOST1521
(for subjects from 7 to 12 years of age)

A trial using a new drug, CDX-011, to treat osteosarcoma that has not responded to treatment or that has come back

1. We have been talking with you about your illness, osteosarcoma. Osteosarcoma is a type of cancer that grows in the cells that produce bones. After doing tests, we have found that you have this type of cancer and it has not gotten better with treatment or it has come back.

2. We are asking you to take part in a research study because you have osteosarcoma and it has not gotten better with treatment or it has come back. A research study is when doctors work together to try out new ways to help people who are sick. In this study we are trying to learn more about how to treat osteosarcoma that has come back. We will do this by giving a new drug to treat osteosarcoma. We do not know how well the new drug will work in children, teens and young adults. That is why we are doing this study.

3. Children who are part of this study will be given an experimental new drug called CDX-011. You will also have scans to see if the cancer is getting worse, staying the same or getting better. There is a possibility that you will also have surgery or radiation therapy (high energy x-rays to kill cancer cells) while you are part of this study. Surgery and radiation therapy are often used to treat osteosarcoma and they are not experimental.

4. Sometimes good things can happen to people when they are in a research study. These good things are called “benefits.” We hope that a benefit to you of being part of this study is that you are able to get rid of the cancer. But we don’t know for sure if there is any benefit of being part of this study.

5. Sometimes bad things can happen to people when they are in a research study. These bad things are called “risks.” Being in this study may involve special risks, which your doctor will discuss with you. Other things may happen to you that we don’t yet know about.

6. Your family can choose to be part of this study or not. Your family can also decide to stop being in this study at any time once you start. There may be other treatments for your illness that your doctor can tell you about. Make sure to ask your doctors any questions that you have.

7. We are trying to learn about how children’s bodies handle the new drug CDX-011. If you are getting treatment at certain hospitals, we will take extra blood samples from you for research tests. These samples will be drawn through your central line if you have one.

   If you are getting treatment at a different hospital, we are asking your permission to collect additional blood. We are trying to learn how child and teenage bodies handle the new drug. These additional blood tests may help children, teens and adults who take this drug in the future. These blood tests will require additional blood draws, which will be drawn through your central line if you have one. You can still be treated on this study even if you don't allow us to collect the extra blood samples for research.

INFORMATION SHEET REGARDING RESEARCH STUDY AOST1521
(for subjects from 13 to 17 years of age)

A trial using a new drug, CDX-011, to treat osteosarcoma that has not responded to treatment or that has come back

1. We have been talking with you about your illness, osteosarcoma. Osteosarcoma is a type of cancer that grows in the cells that produce bones. Recurrent means that the cancer has come back after treatment. After doing tests, we have found that you have this type of cancer.

2. We are asking you to take part in a research study because you have recurrent osteosarcoma. A research study is when doctors work together to try out new ways to help people who are sick. In this study we are trying to learn more about how to treat osteosarcoma that has come back. We will do this by giving a new drug to treat recurrent osteosarcoma. We do not know how well the new drug will work in children, teens and young adults. That is why we are doing this study.

3. Children and teens and young adults who are part of this study will be given an experimental new drug called CDX-011. You will also have scans to see if the cancer is getting worse, staying the same or getting better. There is a possibility that you will also have surgery or radiation therapy (high energy x-rays) while you are part of this study. Surgery and radiation therapy are commonly used to treat osteosarcoma and they are not experimental.

4. Sometimes good things can happen to people when they are in a research study. These good things are called “benefits.” We hope that a benefit to you of being part of this study is that you are able to get rid of the cancer. But we don’t know for sure if there is any benefit of being part of this study.

5. Sometimes bad things can happen to people when they are in a research study. These bad things are called “risks.” Being in this study may involve special risks, which your doctor will discuss with you. Other things may happen to you that we don’t yet know about.

6. You or your family can choose to be part of this study or not. Your family can also decide to stop being in this study at any time once you start. Please talk this over with your parents. Together you can decide if you want to take part in the study or not. There may be other treatments for your illness that your doctor can tell you about. Make sure to ask your doctors any questions that you have.

7. We are trying to learn about how children’s bodies handle the new drug CDX-011. If you are getting treatment at certain hospitals, we will take extra blood samples from you for research tests. These samples will be drawn through your central line if you have one.

   If you are getting treatment at a different hospital, we are asking your permission to collect additional blood. We are trying to learn how child and teenage bodies handle the new drug. These additional blood tests may help children, teens and adults who receive this drug in the future. These blood tests will require additional blood draws, which will be drawn through your central line if you have one. You can still be treated on this study even if you don't allow us to collect the extra blood samples for research.

APPENDIX III: POSSIBLE DRUG INTERACTIONS

The list below does not include everything that may interact with chemotherapy. Study Subjects and/or their Parents should be encouraged to talk to their doctors before starting any new medications, using over-the-counter medicines, or herbal supplements and before making a significant change in diet.

Drugs that may interact with CDX-011 (glembatumumab vedotin)*

• **Antibiotics**
  ○ **Clarithromycin, erythromycin, nafcillin, rifabutin, rifampin, telithromycin**
• **Antifungals**
  ○ **Itraconazole, ketoconazole, posaconazole, voriconazole)**
• **Arthritis medications**
  ○ **Leflunomide, tofacitinib**
• **Anti-rejection medications**
  ○ **Cyclosporine, sirolimus, tacrolimus**
• **Antiretrovirals and antivirals**
  ○ **Atazanavir, boceprevir, darunavir, delaviridine, efavirenz, etravirine, fosamprenavir, indinavir, lopinavir, nelfinavir, nevirapine, ritonavir, saquinavir, Stribild, telaprevir**
• **Anti-seizure medications**
  ○ **Carbamazepine, oxcarbazepine, phenobarbital, phenytoin, primidone**
• **Heart medications**
  ○ **Nicardipine, verapamil**
• **Some chemotherapy (be sure to talk to your doctor about this)**
• **Many other drugs, including the following:**
  ○ **Aprepitant, bosentan, deferasirox, dexamethasone, lomitapide, natalizumab, nefazodone**

Food and supplements that may interact with CDX-011 (glembatumumab vedotin)**
• **Echinacea** • **St. John's Wort** • **Grapefruit, grapefruit juice, Seville oranges, star fruit**

**Sometimes these drugs are used with CDX-011 (glembatumumab vedotin) on purpose. Discuss all drugs with your doctor.*
***Supplements may come in many forms such as teas, drinks, juices, liquids, drops, capsules, pills, and dried herbs. All forms should be avoided.*

APPENDIX IV: PATIENT DRUG INFORMATION HANDOUT AND WALLET CARD

Information for Patients, Their Caregivers and Non-Study Healthcare Team on Possible Interactions with Other Drugs and Herbal Supplements

The patient _____ is enrolled on a clinical trial using the experimental study drug, **CDX-011**. This clinical trial is sponsored by the National Cancer Institute. This form is addressed to the patient, but includes important information for others who care for this patient.

These are the things that you as a healthcare provider need to know:

CDX-011 (glembatumumab vedotin) interacts with certain specific enzymes in your liver* and certain transport proteins that help move drugs in and out of cells**.

- *The enzyme in question is CYP3A4. CDX-011 (glembatumumab vedotin) is metabolized by CYP3A4. Patients must be closely monitored for adverse reaction if strong inhibitors or inducers are administered with CDX-011 (glembatumumab vedotin).
- **The protein in question is P-glycoprotein (P-gp). CDX-011 (glembatumumab vedotin) requires P-gp to move in and out of cells. Patients receiving P-gp inhibitors concomitantly with CDX-011 (glembatumumab vedotin) should be closely monitored for adverse reactions.

To the patient: Take this paper with you to your medical appointments and keep the attached information card in your wallet.

CDX-011 (glembatumumab vedotin) may interact with other drugs which can cause side effects. For this reason, it is very important to tell your study doctors of any medicines you are taking before you enroll onto this clinical trial. It is also very important to tell your doctors if you stop taking any regular medicines, or if you start taking a new medicine while you take part in this study. When you talk about your current medications with your doctors, include medicine you buy without a prescription (over-the-counter remedy), or any herbal supplements such as St. John's Wort. It is helpful to bring your medication bottles or an updated medication list with you.

Many health care providers can write prescriptions. You must tell all of your health care providers (doctors, physician assistants, nurse practitioners, pharmacists) you are taking part in a clinical trial.

These are the things that you and they need to know:
CDX-011 (glembatumumab vedotin) must be used very carefully with other medicines that use certain liver enzymes or transport proteins to be effective or to be cleared from your system. Before you enroll onto the clinical trial, your study doctor will work with your regular health care providers to review any medicines and herbal supplements that are considered "strong inducers/inhibitors or substrates of CYP3A4 or transport protein P-gp".

- Please be very careful! Over-the-counter drugs (including herbal supplements) may contain ingredients that could interact with your study drug. Speak to your doctors or pharmacist to determine if there could be any side effects.
  - Your regular health care provider should check a frequently updated medical reference or call your study doctor before prescribing any new medicine or discontinuing any medicine. Your study doctor's name is _____ and he or she can be contacted at _____.

STUDY DRUG INFORMATION WALLET CARD

You are enrolled on a clinical trial using the experimental study drug *CDX-011 (glembatumumab vedotin)***.** This clinical trial is sponsored by the NCI. *CDX-011 (glembatumumab vedotin)* may interact with drugs that are ***processed by your liver or use certain transport proteins in your body***. Because of this, it is very important to:

- Tell your doctors if you stop taking any medicines or if you start taking any new medicines.
- Tell all of your health care providers (doctors, physician assistants, nurse practitioners, or pharmacists) that you are taking part in a clinical trial.
- Check with your doctor or pharmacist whenever you need to use an over-the-counter medicine or herbal supplement.

CDX-011 (glembatumumab vedotin) interacts with a ***specific liver enzyme called CYP3A4 and transport protein P-gp*** and must be used very carefully with other medicines that interact with ***this enzyme or transporter***.

- Before you enroll onto the clinical trial, your study doctor will work with your regular health care providers to review any medicines and herbal supplements that are considered ***"strong inducers/inhibitors or substrates of CYP3A4 or P-gp transporter.***"
- Before prescribing new medicines, your regular health care providers should go to a frequently-updated medical reference for a list of drugs to avoid, or contact your study doctor.
- Your study doctor's name is _____

  and can be contacted at _____.

REFERENCES

1. Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600-6, 1986
2. Eilber F, Giuliano A, Eckardt J, et al: Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5:21-6, 1987
3. Smeland S, Muller C, Alvegard TA, et al: Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39:488-94, 2003
4. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-90, 2002
5. Lewis IJ, Nooij MA, Whelan J, et al: Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99:112-28, 2007
6. Meyers PA, Heller G, Healey JH, et al: Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 11:449-53, 1993
7. Ochs JJ, Freeman AI, Douglass HO, Jr., et al: cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 62:239-45, 1978
8. Gasparini M, Rouesse J, van Oosterom A, et al: Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer Treat Rep 69:211-3, 1985
9. Pratt CB, Shanks EC: Doxorubicin in treatment of malignant solid tumors in children. Am J Dis Child 127:534-6, 1974
10. Cortes EP, Holland JF, Wang JJ, et al: Amputation and adriamycin in primary osteosarcoma. N Engl J Med 291:998-1000, 1974
11. Souhami RL, Craft AW, Van der Eijken JW, et al: Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350:911-7, 1997
12. Le Deley MC, Guinebretiere JM, Gentet JC, et al: SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 43:752-61, 2007
13. Bacci G, Briccoli A, Ferrari S, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. Oncol Rep 7:339-46, 2000
14. Ferrari S, Smeland S, Mercuri M, et al: Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23:8845-52, 2005
15. Kempf-Bielack B, Bielack SS, Jurgens H, et al: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23:559-68, 2005
16. Marina NM, Pratt CB, Rao BN, et al: Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer 70:2722-7, 1992
17. Bacci G, Briccoli A, Rocca M, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 14:1126-34, 2003
18. Kager L, Zoubek A, Potschger U, et al: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21:2011-8, 2003

19. Mialou V, Philip T, Kalifa C, et al: Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer 104:1100-9, 2005
20. Goorin AM, Delorey MJ, Lack EE, et al: Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol 2:425-31, 1984
21. Meyer WH, Schell MJ, Kumar AP, et al: Thoracotomy for pulmonary metastatic osteosarcoma. An analysis of prognostic indicators of survival. Cancer 59:374-9, 1987
22. Carter PJ, Senter PD: Antibody-drug conjugates for cancer therapy. Cancer J 14:154-69, 2008
23. Celldex Therapeutics I: CDX-011 Investigator's Brochure. Edition 4.0, 2013
24. Kuan CT, Wakiya K, Dowell JM, et al: Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 12:1970-82, 2006
25. Maric G, Rose AA, Annis MG, et al: Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. Onco Targets Ther 6:839-52, 2013
26. Onaga M, Ido A, Hasuike S, et al: Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet, accelerates motility of hepatoma cells. J Hepatol 39:779-85, 2003
27. Qian X, Mills E, Torgov M, et al: Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate. Mol Oncol 2:81-93, 2008
28. Rose AA, Grosset AA, Dong Z, et al: Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 16:2147-56, 2007
29. Rose AA, Pepin F, Russo C, et al: Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 5:1001-14, 2007
30. Singh M, Del Carpio-Cano F, Belcher JY, et al: Functional roles of osteoactivin in normal and disease processes. Crit Rev Eukaryot Gene Expr 20:341-57, 2010
31. Tse KF, Jeffers M, Pollack VA, et al: CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 12:1373-82, 2006
32. Zhou LT, Liu FY, Li Y, et al: Gpnmb/osteoactivin, an attractive target in cancer immunotherapy. Neoplasma 59:1-5, 2012
33. Ripoll VM, Irvine KM, Ravasi T, et al: Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol 178:6557-66, 2007
34. Rose AA, Dong Z, Macdonald PA, et al: GPNMB is Novel Pro-Angiogenic Factor and Therapeutic Target in Breast Cancer." Poster Presentation. Montreal international symposium in angiogenesis and mestastasis Abstract #P21, 2009
35. Selim AA: Osteoactivin bioinformatic analysis: prediction of novel functions, structural features, and modes of action. Med Sci Monit 15:MT19-33, 2009
36. Selim AA, Abdelmagid SM, Kanaan RA, et al: Anti-osteoactivin antibody inhibits osteoblast differentiation and function in vitro. Crit Rev Eukaryot Gene Expr 13:265-75, 2003
37. Li B, Castano AP, Hudson TE, et al: The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair. FASEB J 24:4767-81, 2010
38. Tomihari M, Chung JS, Akiyoshi H, et al: DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. Cancer Res 70:5778-87, 2010
39. Nielsen TO, West RB, Linn SC, et al: Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359:1301-7, 2002
40. Rich JN, Shi Q, Hjelmeland M, et al: Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 278:15951-7, 2003

41. Carter P: Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118-29, 2001
42. Vaughan TJ, Osbourn JK, Tempest PR: Human antibodies by design. Nat Biotechnol 16:535-9, 1998
43. Williams MD, Esmaeli B, Soheili A, et al: GPNMB expression in uveal melanoma: a potential for targeted therapy. Melanoma Res 20:184-90, 2010
44. Pollack VA, Alvarez E, Tse KF, et al: Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol 60:423-35, 2007
45. Kolb EA, Gorlick R, Billups CA, et al: Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer 61:1816-21, 2014
46. Roth M, Barris DM, Piperdi S, et al: Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Pediatr Blood Cancer, 2015
47. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-21, 2010
48. Perez EA, Lerzo G, Pivot X, et al: Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407-14, 2007
49. Cortes J, O'Shaughnessy J, Loesch D, et al: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914-23, 2011
50. Schwartz GJ, Gauthier B: A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 106:522-6, 1985
51. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-47, 2009